1
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Abbreviated Title: Anti-BCMA-CAR T cells 
CC Protocol #: 14-C-0168
OSP#: 1404-1303
IBC#: RD-14-IV-06NCT#: [STUDY_ID_REMOVED]Version Date: September 21, 2017
Amendment: HTitle: A Phase I Clinical Trial of T Cells  Targeting B-Cell Maturation Ant igen for Previously 
Treated Multiple MyelomaPrincipal Investigator:                     James N Kochenderfer, M.D.
A-F
                                                                                          Experimental Transplantation & Immunology Branch
Center for Cancer Research,National Cancer Institute, National Institutes of Health10 Center Drive, Rm. 3-3132, MSC 1203Telephone:  240-760-6062
Email:  Kochendj@mail.nih.gov
Associate Investigators:  
Jennifer Mann, C.R.N.P., ETIB, CCR, NCI, NIHA-E Maryalice Stetler-Stevenson M.D., PhD., DTM, 
CCR , NCI, NIHE-F
Ronald Gress, M.D., ETIB, CCR, NCI, NIHA-FStephanie Cotton, R.N., OCD, CCR , NCI, NIHA-B
Steven Pavletic, M.D., ETIB, CCR , NCI, NIHA-FIrina Maric, M.D, CCR, NCI, NIHE-F
Brenna Hansen, R.N., OCD, CCR, NCI, NIHA-BDennis Hickstein, M.D., ETIB, CCR, NCI, NIHA-F
Jennifer Nicole Brudno,M.D., OCD, CCR, NCI, NIH 
A-F David Stroncek, M.D., DTM, CC, NIHE-F
Daniele Avila, C.R.N.P., ETIB, CCR, NCI, NIHA-ESeth Steinberg, Ph.D., OCD, CCR, NCI, NIHB, E
Fran Hakim, Ph.D, ETIB, CCR, NCI, NIHE-FConstance Yuan M.D., PhD., DTM, CC, NIHE-F
Bazetta Blacklock-Schuver, R.N., OCD, CCR, NCI, 
NIHA-B Thomas Hughes, Pharm.D., CC, NIHA-B
Steven Feldman M.D., SB, CCR, NCI, NIHA-FTracey Chinn, R.N, ETIB, CCR, NCI, NIHA-B
Referral Contact and Study Coordinator: Judith Lawrence, R.N.
240-760-6173, Fax: 301-451-5667
Email: judith.lawrence@nih.gov
2
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Non-NIH Associate Investigator:
Judith Lawrence, R.N, Leidos Inc., A-B
For each person listed above, roles  are identifie d with the app ropriate letter
A.Obtain information by intervenin g or interacting with living in dividuals for research purposes
B.Obtaining identifiable private information about living individ uals
C.Obtaining the voluntary inform ed consent of individuals to be s ubjects
D.Makes decisions about subject eligibility
E.Studying, interpreting, or analyzi ng identifiable private information or data/sp ecimens for 
research purposes
F.Studying, interpreting, or analy zing de-identified data or spec imens for research purposes
G.Some/all research activities performed outside NIH
Investigational Agents: 
Drug Name: Anti-BCMA-CAR-
transduced autologous
peripheral blood lymphocytes (PBL)
IND Number: 16041
Sponsor: Center for Cancer Research
Commercial Agents: Cyclophosphamide, Fludarabine
3
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
PRÃ‰CIS 
Background:
xMultiple myeloma (MM) is a malignancy of plasma cells. 
xMM is nearly always incurable.
xT cells can be genetically modified to express chimeric antigen  receptors (CARs) that 
specifically target malignancy-associated antigens.
xAutologous T cells genetically m odified to express CARs targeti ng the B-cell antigen CD19 
have caused complete remissions  in a small numbe r of patients w ith leukemia or lymphoma.  
These results demonstrate that C AR-expressing T cells have anti -malignancy activity in 
humans.
xB-cell maturation antigen (BCMA) is a protein expressed by norm al plasma cells and the 
malignant plasma cells of multiple myeloma.
xBCMA is not expressed by normal c ells except for plasma cells a nd some mature B cells.
xWe have constructed an anti-BCMA CAR that can specifically reco gnize BCMA-expressing 
target cells in vitro and eradicat e BCMA-expressing tumors in m ice.
xAnti-BCMA-CAR-expressing T ce lls have not been previously teste d in humans.
xWe hypothesize that anti-BCMA-CAR-expressing T cells will speci fically eliminate BCMA-
expressing MM cells in patients
xPossible toxicities include cytokine-associated toxicities such  as fever, hypotension, and 
neurological toxicities.  Elimin ation of normal pl asma cells and unknown toxicities are also 
possible.
Objectives:
Primary
xDetermine the safety and feasibility of administering T cells exp ressing an anti-BCMA CAR 
to patients with MM.
SecondaryxEvaluate the in vivo persistence of anti-BCMA CAR T cells
xAssess for evidence of anti-myeloma activity by anti-BCMA CAR T cells
Eligibility:
xPatients must have meas urable MM defined as a serum M-protein Â•0.4 g/dL or a urine M-
proteinÂ•PJKRXUVRUDQLQYROYHGVHUXPIUHHOLJKWFKDLQ)/&OH YHO Â•PJG/
(provided FLC ratio is abnormal) or a biopsy-proven plasmacytom a.
xPatients must have previously recei ved at least 3 different treat ment regimens for MM.
xPatients must have a  normal creatinine a nd a normal cardiac eje ction fraction.
xAn ECOG performance status of 0 -2 is required.
4
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xPatients on any anticoa gulant medications except aspirin are no t eligible.
xNo active infections are allowed.
x$EVROXWHQHXWURSKLOFRXQWÂ• P/SODWHOHWFRXQWÂ• 45,000/P/KHPRJORELQÂ•JG/
x$/7DQG$67Â” 2.5-fold higher than the upper limit of normal
xAt least 14 days must elapse betw een the time of any prior syst emic treatment (including 
corticosteroids) and the r equired leukapheresis.
xAt least 14 days must elapse betw een the time of any prior systemic treatment (including 
corticosteroids) and initia tion of protocol treatment.
xBone marrow plasma cells must be 30% or less of total bone marro w cells 30 days or less 
prior to the start of protocol treatment.
xThe patientâ€™s MM will need to be  assessed for BCMA expression b y flow cytometry or 
immunohistochemistry performed at the NIH.  If unstained, paraf fin-embedded bone marrow 
or plasmacytoma sections are ava ilable from prior biopsies, the se can be use d to determine 
BCMA expression by immunohistoche mistry; otherwise patients will  need to come to the 
NIH for a bone marrow biopsy or other biopsy of a plasmacytoma to  determine BCMA 
expression.  The sample for BCMA e xpression can come from a bio psy obtained at any time 
before enrollment.
Design:
xThis is a phase I dose-escalation trial
xPatients will underg o leukapheresis
xT-cells obtained by leuk apheresis will be genetically modified to express an anti-BCMA 
CAR
xPatients will receive a lymphocyt e-depleting chemotherapy condi tioning regimen with the 
intent of enhancing the activity  of the infused anti-BCMA-CAR-e xpressing T cells.
xThe chemotherapy conditioning  regimen is cyclophosphamide 300 m g/m2daily for 3 days 
and fludarabine 30 mg/m2daily for 3 days.  Fludarabine w ill be given on the same days a s 
the cyclophosphamide.
xTwo days after the chemotherapy ends, patients will receive an infusion of anti-BCMA-
CAR-expressing T cells.
xThe initial dose level of this  dose-escalation trial will be 0. 3x106CAR+ T cells/kg of 
recipient bodyweight.
xThe cell dose administered will be escalated until a maximum to lerated dose is determined
for patients in which less th an 50% of total bone marrow cells are plasma cells. With 
Amendment C, all patients with 50%  or greater bone marrow plasma  cells will receive 3x106
anti-BCMA CAR T cells/kg.
xFollowing the T-cell infusion, the re is a mandatory 9-day inpat ient hospitalization to monitor 
for toxicity.
5
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xOutpatient follow-up is pla nned for 2 weeks, and 1, 2, 3, 4, 6, 9, and 12 months after the 
CAR T-cell infusion.
xRepeat treatments are possible fo r patients with r esidual MM and no greater than grade 2 
toxicity with an initial treatment.
xRe-enrollment will be a llowed for a small number of subjects.
6
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
TABLE OF CONTENTS 
PRÃ‰CIS......................................................... .................................................................................. 3  
TABLE OF CONTENTS................................................................................................................ 6  
1 INTRODUCTION ................................................................................................................ 11  
1.1 Study Objectives ............................................... ............................................................. 11  
1.1.1  Primary Objective .............................................. ..................................................... 11  
1.1.2  Secondary Objectives.............................................................................................. 11  
1.2 Background and Rationale ....................................... ...................................................... 11  
1.2.1  Introduction............................................................................................................. 11  
1.2.2  Multiple myeloma epidemiol ogy and standard treatment ...................................... 11  
1.2.3  Allogeneic transplantation for MM .............................. .......................................... 12  
1.2.4  T-cell gene therapy ............................................ ..................................................... 13  
1.2.5  Chimeric antigen receptors ..................................................................................... 13  
1.2.6  BCMA..................................................................................................................... 15  
1.2.7  Anti-BCMA CAR development and preclinical testing ......................................... 18  
1.2.8  Rationale for immunosuppressive chemother apy and selection of l ymphocyte-
depleting chemotherapy regimen................................. ......................................................... 24  
1.2.9  Rationale for dose-escalation.................................. ................................................ 25  
1.2.10  Summary of risks and po tential benefits........................ ......................................... 26  
2 ELIGIBILITY ASSESSMENT AND ENROLLMENT.......................... ............................. 26  
2.1 Eligibility Criteria ........................................... ............................................................... 26  
2.1.1  Inclusion Criteria .................................................................................................... 26  
2.1.2  Exclusion criteria: ................................................................................................... 28  
2.2 Screening Evaluation........................................... ........................................................... 29  
2.3 Registration Procedures........................................ .......................................................... 30  
3 STUDY IMPLEMENTATION ........................................... ................................................. 30  
3.1 Study Design .................................................................................................................. 30  
3.1.1  General study plan ............................................. ..................................................... 30  
3.1.2  Protocol schema................................................ ...................................................... 32  
3.1.3  Dose Limiting Toxicity......................................... .................................................. 33  
3.1.4  Dose Escalation................................................ ....................................................... 33  
3.2 Dose Modifications/Delay....................................... ....................................................... 35  
7
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.3 Drug Administration ...................................................................................................... 36  
3.3.1  Leukapheresis .................................................. ....................................................... 36  
3.3.2  Anti-BCMA-CAR-expressing T-cell preparation.................... ............................... 36  
3.3.3  Conditioning chemotherapy and anti-BCMA CAR T-cell administratio n-this can be 
either inpatient  or outpatient ................................. ................................................................3 7  
3.3.4  Potential repeat treatment ..................................... .................................................. 38  
3.4 Protocol Evaluation........................................................................................................ 38  
3.4.1  Baseline evaluations and interventions......................... .......................................... 38  
3.4.2  Studies to be performed during the mandatory 9-day inpatient ad mission after cell 
infusion 40  
3.4.3  Post-infusion outpatient evaluation............................ ............................................. 40  
3.5 Study Calendar ............................................................................................................... 43  
3.6 Gene-therapy-sp ecific follow-up................................ .................................................... 47  
3.7 Criteria for Removal from Protocol Therapy and Off Study Criter ia............................ 47  
3.7.1  Criteria for removal from protocol therapy ..................... ....................................... 47  
3.7.2  Off-Study Criteria ............................................. ...................................................... 48  
3.7.3  Off Protocol Therapy and Off-Study Procedure..................................................... 48  
4 CONCOMITANT MEDICATIONS/MEASURES............................... ............................... 48  
4.1 Antibiotic prophylaxis.................................................................................................... 48  
4.2 Blood product support.......................................... .......................................................... 49  
4.3 Anti-emetics ...................................................................................................................4 9  
4.4 Granulocyte colony-stimulating factor.......................... ................................................. 49  
4.5 Avoidance of corticosteroids................................... ....................................................... 49  
4.6 Guidelines for management of common acute toxicities that occur  after CAR T cell 
infusions.................................................................................................................................... 50  
5 BIOSPECIMEN COLLECTION......................................... ................................................. 50  
5.1 CORRELATIVE STUDIES FOR RESEARCH............................... ............................. 50  
5.1.1  Biospecimen collection before the  start of the conditioning che motherapy:.......... 50  
5.1.2  Biospecimen collection after an ti-BCMA-CAR T-cell infusion during the required 
hospitalization................................................ ....................................................................... 50  
5.1.3  Biospecimen collection durin g outpatient follow-up............. ................................. 51  
5.1.4  Immunological Testing .......................................... ................................................. 51  
5.1.5  Additional biopsies a nd additional blood draws................. .................................... 52  
8
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
5.1.6  Future studies................................................. ......................................................... 53  
5.2 Sample Storage, Tracking and Disposition.................................................................... 53  
5.2.1  Storage/Tracking in the Preclin ical Development and Clinical Mo nitoring Facility 
(PDCMF) ........................................................ ...................................................................... 53  
5.2.2  Protocol Completion/Sample Destruction ......................... ..................................... 54  
5.2.3  Samples for Genetic/Genomic Analysis ........................... ...................................... 54  
6 DATA COLLECTION AND EVALUATION..................................................................... 55  
6.1 Data Collection................................................ ............................................................... 55  
6.1.1  Adverse event recording: ....................................... ................................................. 56  
6.2 Genomic Data Sharing Plan ...................................... ..................................................... 56  
6.3 Response Criteria .............................................. ............................................................ 56  
6.3.1  Important Considerations on response criteria .................. ..................................... 56  
6.3.2  International Myeloma Workin g Group uniform response criteria: . ...................... 57  
6.4 Toxicity Criteria ............................................................................................................. 59  
7 SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING PLAN
60 
7.1 Definitions...................................................................................................................... 60  
7.1.1  Adverse Event.................................................. ....................................................... 60  
7.1.2  Suspected adverse reaction ..................................... ................................................ 60  
7.1.3  Unexpected adve rse reaction .................................... .............................................. 60  
7.1.4  Serious..................................................................................................................... 61  
7.1.5  Serious Adverse Event.......................................... .................................................. 61  
7.1.6  Disability..................................................... ............................................................ 61  
7.1.7  Life-threatening advers e drug experience....................... ........................................ 61  
7.1.8  Protocol Deviation (NIH Definition)............................ .......................................... 61  
7.1.9  Non-compliance (NIH Definition)................................ .......................................... 61  
7.1.10  Unanticipated Problem.......................................... .................................................. 61  
7.2 NCI-IRB and Clinical Director Reporting ........................ ............................................. 62  
7.2.1  NCI-IRB and NCI CD Expedited Reporting of Unanticipated Problem s and Deaths
62 
7.2.2  NCI-IRB Requirements for PI Reporting at Continuing Review ..... ...................... 62  
7.2.3  NCI-IRB Reporting of IND Safety Reports........................ .................................... 62  
7.3 IND Sponsor Reporting Criteria .................................................................................... 63  
9
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
7.3.1  Reporting Pregnancy............................................................................................... 63  
7.4 Institutional Biosafety Committee (IBC) Reporting Criteria......................................... 64  
7.4.1  Serious Adverse Event Reports to IBC........................... ........................................ 64  
7.4.2  Annual Reports to IBC............................................................................................ 64  
7.5 Data and Safety Monitoring Plan................................ ................................................... 65  
7.5.1  Principal Investigator/Research Team ........................... ......................................... 65  
7.5.2  Sponsor Monitoring Plan ........................................ ................................................ 65  
7.5.3  Safety Monitoring Committee (SMC) .............................. ...................................... 66  
8 STATISTICAL CONSIDERATIONS.................................................................................. 66  
9 COLLABORATIVE AGREEMENTS ................................................................................. 68  
9.1 Cooperative Research and Development Agreement (CRADA)......... .......................... 68  
10 HUMAN SUBJECTS PROTECTIONS ............................................................................... 68  
10.1  Rationale For Subject Selection ................................................................................. 68  
10.2  Participation of Children ............................................................................................ 69  
10.3  Participation of Subjects Unable to Give Consent ............... ...................................... 69  
10.4  Evaluation of Benefits an d Risks/Discomforts................... ........................................ 69  
10.5  Consent and Assent Process and Documentation................... .................................... 70  
10.5.1  Telephone re-consent procedure ................................. ............................................ 70  
10.5.2  Short form consent process for  non-English speaking patients.............................. 70  
11 PHARMACEUTICAL INFORMATION..................................... ........................................ 71  
11.1  Retroviral Vector Containing  the anti-BCMA CAR Gene............ ............................. 71  
11.2  Cyclophosphamide ..................................................................................................... 71  
11.2.1  Source ......................................................... ............................................................ 71  
11.2.2  Toxicities................................................................................................................. 71  
11.2.3  Formulation and preparation.................................... ............................................... 72  
11.2.4  Stability and Storage............................................................................................... 72  
11.2.5  Administration procedures...................................... ................................................ 72  
11.3  FLUDARABINE.................................................... .................................................... 72  
11.3.1  Source ......................................................... ............................................................ 72  
11.3.2  Toxicity................................................................................................................... 73  
11.3.3  Formulation and preparation.................................... ............................................... 73  
11.3.4  Stability and Storage............................................................................................... 73  
10
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
12 Refere nces..................................................... ........................................................................ 74  
13 Appendices............................................................................................................................ 82  
13.1  Appendix A-Performance  Status Criteria......................... .......................................... 82  
13.2  APPENDIX B: Data Collection E lements Required By Protocol...... ........................ 83  
13.3  Appendix C:   Guidelines for man agement of common toxicities th at occur after CAR 
T-cell infusions ............................................... .......................................................................... 85  
13.4  Appendix D:   Infusion Instructions ............................ ............................................... 89  
11
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.1.1 Primary Objective
Determine the safety and feasibility of administering T cells e xpressing an anti-B-cell maturation 
antigen (BCMA) chimeric antigen receptor (CAR) to patients with  multiple myeloma (MM).
1.1.2 Secondary Objectives
xEvaluate the in vivo persisten ce and ex vivo function of T cell s expressing an anti-BCMA 
CAR.
xAssess infusions of anti-BCMA-CAR -expressing T ce lls for anti-MM activity.
1.2 BACKGROUND AND RATIONALE
1.2.1 IntroductionMultiple myeloma (MM) is a malignancy of plasma cells that is a lmost always incurable.  New 
therapies are needed for MM.  Regressions of MM occurring in th e setting of allogeneic stem 
cell transplantation (alloHSCT), and particularly after allogen eic donor lymphocyte infusions 
(DLIs), provide evidence that cellular immune responses can hav e a clinically significant anti-
myeloma effect, but alloHSCT is associated with a significant t ransplant-related mortality and by 
chronic graft-versus-host disease.
1,2Several patients have  obtained lengthy complete remissions 
of lymphoma or chronic lymphocytic  leukemia after infusions of autologous T cells that were 
genetically modified to express chimeric antigen receptors (CAR s) targeting the B-cell antigen 
CD19.3,4The lasting complete remissions of MM that sometimes occur in t he setting of 
alloHSCT and the encouraging early results obtained treating pa tients with anti-CD19-CAR-
expressing T cells provide a rationale for attempting to develo p CAR-T-cell therapies for MM.  
B-cell maturation antigen (BCMA) is a protein that is expressed  by MM cells.5BCMA is also 
expressed by normal plasma cells and by some normal B cells, but BCMA is not expressed by 
other normal cells.5The very limited expression of BCMA in normal tissues makes BCM A a 
very promising target for CAR-T-cell therapies.  We have develo ped an anti-BCMA CAR, and 
we have demonstrated that T cells  expressing this CAR have BCMA -specific activity in vitro 
and in vivo.5Anti-BCMA-CAR-expressing T cells can eradicate MM tumors in mic e.5We 
propose to conduct a phase I clinical trial of anti-BCMA-CAR-ex pressing T cells.  This clinical 
trial will enroll patients with advanced MM that is progressive  despite at least 3 prior therapies.  
Patients enrolled on the trial will receive a single cycle of c hemotherapy that is designed to 
decrease endogenous lymphocyte counts because extensive evidenc e exists that depleting 
endogenous lymphocytes, and possibly other cells, with chemothe rapy or total body irradiation 
dramatically increased the anti-tumor activity of adoptively tr ansferred T cells.6-8After the 
lymphocyte-depleting chemothera py, patients will receive an inf usion of autologous anti-
BCMA-CAR T cells.  The T cell dose will escalate with sequentia l cohorts of patients until a 
maximum tolerated dos e is determined.
1.2.2 Multiple myeloma epidemio logy and standard treatment
12
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Multiple myeloma (MM) is a neoplas m of monoclonal plasma cells.9,10For MM to be 
diagnosed, a patient must have a  proliferation of monoclonal pl asma cells plus other 
abnormalities such as an emia, renal insufficiency, hypercalcemi a, and lytic bone lesions.10MM
is the second most frequently occu rring hematologic cancer in t he United States (U.S.).10An 
estimated 22,350 new cases of MM will  be diagnosed in the U.S. in 2013, and an estimated 
10,710 patients will die from MM in the U.S. in 2013.11Recent improvements in the therapy of 
MM have occurred.9,10,12These improved treatments have i ncreased the median survival of  
patients with newly-diagnosed MM from 3 years to slightly over 5 years, although the prognosis 
of newly-diagnosed MM patients varies widely.10,12
Current standard non-transplant th erapies for MM include variou s combinations of 
dexamethasone, bortezo mib and its analogs, lenalidomide and its  analogs, prednisone, 
melphalan, and cyclophosphamide.9,10,12,13Myeloablative doses of chemotherapy followed by 
autologous stem cell transplanta tion is a standard therapy for MM patients with good 
performance status, and adequ ate bone marrow stem cells.10,12Compared to standard doses of 
chemotherapy for first treatme nt of MM, administration of myelo ablative doses of chemotherapy 
followed by autologous stem cell transplantation improved progr ession-free survival in most 
trials and overall survival in some trials.10,12Myeloablative chemotherapy followed by 
autologous transplantation can a lso be used as a treatment for relapsed MM in some cases.10,12,14
Use of the International Unifor m Response Criteria for Multiple  Myeloma is the most common 
approach for assessing clinical outcomes in MM.15Despite the recent improvements in 
treatment, MM remains an almos t always incurable disease.12,16,17Patients obtaining remissions 
of MM almost always relapse.12The median overall survival of patients with relapsed MM 3 
years or less.16Survival is shorter for patient s treated with lenalidomide plus  dexamethasone 
who have received at least 2 prior lines of therapy compared to patients who received only one 
prior line of therapy.18In patients with MM that was re fractory to bortezomib, the medi an 
overall survival was only 9 months when the patient  was also ei ther ineligible for thalidomide or 
lenalidomide, or the pa tient had MM that was relapsed or refract ory to thalidomide or 
lenalidomide.17Utilizing the immune system to treat MM is one possible way to improve 
therapy of MM.  So far, the clearest evidence of activity of th e immune system against MM 
comes from allogeneic transplantation studies.
1.2.3 Allogeneic transplantation for MM
Allogeneic stem cell transplant ation (alloHSCT) can cure a frac tion of patients with MM.19,20
Myeloablative alloHSCT can induce long-term complete remissions  of MM, but also has a 
transplant-related mortality  rate (TRM) of 20% to 50%.19,20The high TRM of myeloablative
alloHSCT led investigators to t est nonmyeloablative alloHSCT fo r MM.19-21A commonly used 
transplantation strategy is to ad minister myeloablative chemotherapy plus an autologous stem 
cell transplant and then to conduc t a nonmyeloablative alloHSCT  a short time later.1,19,20in 
some studies, this strategy has  been shown to yield higher rates of progression-free and overall 
survival when compared to the s trategy of 2 sequential autologo us stem cell transplants.1,21One 
recent trial showed an 8-year progression-free survival rate of  22% for patients receiving an 
autologous transplant followed b y a nonablative alloHSCT compar ed to an 8-year progression-
free survival of 12% for patients receiving sequential autologous transplants.1These results 
1 3 
A b brevi ate d Title: A nti- B C M A- C A R T cells 
Versi o n D ate: Se pte m ber 2 1, 2 0 1 7 
s h o we d a statisticall y si g nifica nt a d va nta ge f or t h e a ut ol o g o us  f oll o we d b y all o H S C T strate g y, 
b ut als o p oi nt o ut t hat t he vast m aj orit y of p atie nts are n ot c ure d b y eit her a p pr oac h.  
Beca use ma n y n o n m yel oa blati ve tra n s pla nt r e gi me ns  t hat ha ve bee n us e d t o treat M M i ncl u de 
ver y l o w d oses of ra diati o n or c he m ot her a p y, n o n m yel oa bl ati ve a ll o H S C Ts de pe n d o n a n 
i m m u n ol o gic graft- v ers us- m yel o ma eff ect, a n d re missi o ns of M M t hat occ ur after 
n o n m yel oa bl ati ve all o H S C T pr o vi de  e vi de nce t hat i m m u ne res p o nse s ca n b e eff ecti ve at 
eli mi nati n g M M. 1, 1 9, 2 0 Direct e vi de n ce t hat l y m p h oc yt es ca n eli mi nate M M c o mes fr o m d o n or 
l y m p h oc yte i nf usi o ns ( D LIs). 2, 2 0 T we nt y-t w o t o t we nt y- ei g ht per ce n t of p atie nts recei vi n g D LIs 
t o treat persisti n g M M after all o H S C T ha ve ac hie ve d c o m plete re missi o ns ( C Rs). 2, 1 9, 2 0 Of n ote, 
s o me of t hese patie nt s o btai ni n g C Rs after D LIs di d n ot recei ve  a n y ot her t h era pies ar o u n d t he 
ti me of t heir D LI. 2T hes e res ults de m o nstrate t he a bilit y of t he i m m u ne s yste m t o e ra dicat e M M.  
U nf ort u natel y, b ot h all o H S C T a n d D LI s utilize all o ge nei c l y m p h o c yt es; t heref ore, t he y are 
ass ociate d wit h t he s o meti mes fa tal c o m plicati o n of graft- v ers u s- h ost disease 2, 1 9, 2 0 ; i n a d diti o n 
m ost patie nts recei vi n g D LIs f or M M d o n ot o bt ai n C Rs, s o de vel o pi n g of a n effecti ve 
a ut ol o g o us cell ular i m m u ne t hera p y f or M M w o ul d be a maj or a d v a nce. 
1. 2. 4 T-cell ge n e t hera p y 
T cells ca n b e pre p are d f or a d o p ti ve tra nsf er b y ge neticall y m o dif yi n g t h e T cells t o e x press 
rece pt ors t hat s pecificall y r ec o g nize t u m or-ass oci ate d a nti ge ns .2 2- 2 9 Ge netic m o dificati o n of T 
cells is a q uic k a n d r e lia ble pr ocess, a n d cli nical trials of g e neticall y m o difi e d T cells tar geti n g a 
variet y of mali g na n cies h a ve bee n carrie d o ut. 3, 4, 2 6, 3 0, 3 1 Ge neticall y m o difie d a nti ge n-s pecifi c T 
cells ca n be ge nerate d fr o m pe ri p heral bl o o d m o n o n uclear cells ( P B M C) i n s ufficie nt n u m bers 
f or cli nical treat me nt wit hi n 1 0 da ys. 3Ge neticall y m o dif yi n g T cells wit h ga m maretr o vir us es 
c o nsiste ntl y ca uses hi g h a n d s ustai ne d le vels of e x pressi o n of i ntr o d uce d ge nes wit h o ut i n vitr o 
selecti o n 4, 3 0, 3 2, 3 3 , a n d ge n etic m o dificati o n of mat ur e T cells wit h ga m maretr o vir uses has a l o n g 
hist or y of safet y i n h u ma ns. 3 4- 3 6 T here ar e t w o ge neral a p pr oac h es f or ge n erati n g a nti ge n- 
s pecific T cells b y ge neti c m o di ficati o n:   i ntr o d uci n g ge n es e nc o di n g nat ur al T cell rece pt ors 
( T C Rs) or i ntr o d uci n g ge nes e nc o di n g c hi meric a nti ge n r ece pt ors  ( C A Rs). 2 3, 2 5, 2 6, 2 8 C A Rs are 
f usi o n pr otei ns i nc or p orati n g a n ti ge n r ec o g niti o n m oieties a n d T cell acti v ati o n d o mai ns. 2 7, 3 7- 3 9 
T he a nti ge n- bi n di n g d o m ai ns of m ost C A Rs c urre ntl y u n der g oi n g c li nical a n d precli nical 
de vel o p me nt ar e a nti b o d y varia ble r e gi o ns. 2 3, 2 7, 3 7, 3 9 T C Rs rec o g nize pe pti des prese nte d b y 
h u ma n le u k oc yte a nti ge n ( H L A) m o lec ules; t heref ore, T C Rs are H L A-r estricte d, a n d a p artic ular 
T C R will o nl y be us ef ul i n patie nts e x pressi n g cert ai n H L A m ole c ules 2 3, 2 5, 2 6, 3 7 , w hic h li mits t he 
n u m ber of patie nts w h o c o ul d be treate d wit h T cells ge neticall y m o difie d t o e x press a T C R.  I n 
c o ntrast, C A Rs rec o g nize i ntact  cell-s urface pr otei ns a n d gl yc o li pi ds, s o C A Rs are n ot H L A- 
restricte d, a n d C A Rs ca n be use d t o treat p atie nts re gar dl ess o f t heir H L A t y p es. 2 3, 2 6, 4 0- 4 2 
1. 2. 5 C hi meric a nti ge n rece pt ors 
Precli nical e x peri me nts e val uati n g C A R-e x pressi n g T cells as ca n cer t hera p y w ere i nitiate d i n 
1 9 9 3. 4 3, 4 4 T hese e x peri me nts le d t o a cli nical trial of C A R-tra ns d uce d T c ells tar geti n g t he -
f olate rece pt or o n o v aria n ca nce r cells; n o t u m or re gressi o ns w ere o bser ve d d uri n g t his cli nical 
trial. 4 5 C A Rs t hat were ca pa ble of rec o g niz i n g a v ariet y of t u m or- ass oci ate d a nti ge ns h a ve bee n 
14
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
evaluated in many centers.23,37Preclinical studies have assessed a wide variety of factors tha t 
could affect in vivo function of CAR -expressing T cells.  Multi ple approaches for inserting CAR 
genes into T cells by using gammaretroviruses4,30,32-34,46-48, lentiviruses3,49-52, or transposon 
systems53,54have been assessed.  B ecause all methods of T-cell genetic modi fication require a 
period of in vitro culture, various T-cell culture techniques h ave been evaluated.3,46,55Different 
portions of CARs including antig en-recognition moieties, extrac ellular structural components, 
costimulatory domains such as th e cytoplasmic portion of the CD 28 protein, and T-cell-
activation moieties su ch as the signaling domains of the CD3 ]protein can all be important to the 
in vivo function of CAR-expressing  T cells, and all of these po rtions of CARs remain the subject 
of intensive investigation.37,46,50,56-58Much of the preclinical work e valuating CARs has been 
performed with CARs targeting the B-cell antigen CD19.7,46-48,53,59,60Data suggesting that T-cell 
costimulation played an important r ole in the activity of CAR-expressing T cells in vivo led 
investigators to add signaling mo ieties from the costimulatory molecule CD28 to CARs.48,57
These studies showed that adding  CD28 moieties to CARs enhanced antigen-specific cytokine 
production and proliferation b y anti-CD19 CAR T cells.57,61,62T cells expressing CARs with 
CD28 signaling moieties and CD3 ]signaling domains were more effective than T cells 
expressing CARs without CD28 moi eties at eradicating human leuk emia cells from mice.61,62
Subsequently, CARs incorporating  other signaling domains from c ostimulatory molecules such 
as 4-1BB (CD137) were developed.49Anti-CD19 CARs containing t he signaling domains of 
both 4-1BB and CD3 ]were superior to CARs containing the signaling domains of CD3 ]without 
any costimulatory domains at erad icating human malignant cells from mice.50,56Similar to 
CD28, including 4-1BB signaling moieties in CARs led to increas ed CD19-specific proliferation 
and enhanced in vivo persistence.50In contrast to T cells expre ssing a CAR with a CD28 
moiety, the increased in vitro proliferation and prolonged in v ivo persistence of T cells 
expressing a 4-1BB-containing C AR occurred whether or not the T cells were exposed to the 
antigen that the CAR recognized.50,56
Results from several clinical trials of anti-CD19 CAR T cells h ave been reported to date in peer-
reviewed papers; these papers ha ve all reported results from pa tients receiving autologous CAR-
modified T cells.3,4,30,32,33,63,64The first evidence of antigen-s pecific activity of anti-CD19 CA R 
T cells in humans was generated du ring a clinical trial at the National Cancer Institute in a 
patient who experienced a drama tic regression of advanced folli cular lymphoma.32This clinical 
trial utilized a gamma retroviral vector to i ntroduce an anti-CD 19 CAR containing the signaling 
domains of the CD28 and CD3 ]molecules.32The anti-CD19 CAR-transduced T cells were 
prepared by using a 24-day in v itro culture process.  The clini cal treatment reg imen consisted of 
lymphocyte-depleting chemothera py followed by an infusion of anti-CD19 CAR T cells and a 
course of high-dose interleukin-2 (IL-2).  The first patient treated on this protocol had a large 
disease burden of follicular lym phoma.  This first patient expe rienced no acute toxicities except 
for a low grade fever that lasted for 2 days, and he obtained a  partial remission ( PR) that lasted 
for 32 weeks.32Bone marrow biopsies revealed a  complete elimination of extensi ve bone 
marrow lymphoma that was present before treatment; in addition,  normal B-lineage cells were 
completely eradicated from the bone marrow.32The bone marrow B-cell eradication was 
confirmed by flow cytometry, a nd it persisted for over 36 weeks .32B cells were also completely 
absent from the blood during this time, while T c ells and other  blood cells recovered rapidly.32
Seven months after the anti-CD 19 CAR T cell infusion, progressi ve lymphoma was detected in 
the patientâ€™s cervical lymph nodes .  The lymphoma remained CD19+, so the patient was treated a 
15
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
second time with anti-CD19 CAR T  cells.  The first and second treatment regimens were the 
same except the patient received a higher dose of cells with the second treatment.  After the 
second treatment, the patient obtained a second ongoing partial  remission.4   
Seven more patients we re subsequently treated with the same reg imen of chemotherapy, anti-
CD19 CAR T cells, and high-dose IL-2.4In 4 of 7 evaluable patients  on the trial, administration 
of anti-CD19 CAR T cells was a ssociated with a profound and pro longed B-cell depletion.4,32In 
all 4 patients with B-cell depl etion, the depletion lasted for over 36 weeks. The B-cell depletion 
could not be attributed to the chemotherapy that was administer ed because blood B-cells 
recovered to normal levels i n 8 to 19 weeks in patients receivi ng the same chemotherapy plus 
infusions of T cells targeting N Y-ESO or gp100, which are antige ns that are not expressed by B 
cells.32Because normal B cells express C D19, prolonged normal B-cell depletion after anti-
CD19 CAR T-cell infusions demonstr ated that CAR-expressing T ce lls had a powerful ability to 
eradicate CD19+cells in humans.  All of the patient s with long-term B-cell dep letion obtained 
either complete or pa rtial remissions of the ir malignancies, an d the 4 patients with long-term B 
cell depletion also de veloped hypogammagl obulinemia.  Hypogamma globulinemia in these 
patients was routinely treated w ith infusions of intravenous im munoglobulins.  Of the eight 
patients treated, seven patients w ere evaluable for malignancy response; the one patient who was 
not evaluable died with pneum onia caused by influenza A.4Six of the seven evaluable patients 
had remissions of their  malignancies.  Two of  the remissions we re complete remissions (CRs) of 
CLL.4Both of these CRs were confirmed by multicolor flow cytometry o f bone marrow cells.4
One of these CRs lasted 24 months, and the other is ongoing at 30 months.4Most patients 
treated with this regimen of che motherapy, anti-CD19 CAR T cell s, and IL-2 experienced 
significant acute toxicities in cluding fever, hypotension, and neurological toxicities such as 
delirium and obtundation.4All of these toxicities peake d within 10 days after the cell in fusion 
and resolved less than 3 week s after the cell infusion.4These acute toxicities correlated with
serum levels of the i nflammatory cytokines tumor necrosis facto r and interferon- J, and T cells 
producing these inflammatory cyt okines in a CD19-specific manner were detected in the blood 
of patients after the anti-CD19 CAR T cell infusions.4
1.2.6 BCMA
One candidate antigen for immunot herapies of MM is B-cell matur ation antigen (BCMA, 
CD269) 65,66.  BCMA RNA was detected univers ally in MM cells, and BCMA prot ein was 
detected on the surface of plasma  cells from multiple myeloma p atients by several investigators 
67-70.  BCMA is a member of the tumor  necrosis factor receptor (TNF)  superfamily 71,72.  BCMA 
binds B-cell activating factor (BAFF) and a pr oliferation induc ing ligand (APRIL) 72-74.  Among 
nonmalignant cells, BCMA has been  reported to be  expressed most ly by plasma cells and subsets 
of mature B cells 65,66,73,75,76.  Mice deficient in BCMA were h ealthy and had a normal physica l 
appearance 77,78.  BCMA-deficient mice had normal numbers of B cells, but survi val of long-
lived plasma cells was impaired 75,77.
A critical factor for any antigen being considered as a target for immunotherapies is the antigenâ€™s 
expression pattern in nor mal tissues.  BCMA has been reported to be expressed in plasma cells 
and in some B cells but to othe rwise have limited expression 65-67,76.  To more completely assess 
the expression pattern of BCMA, w e performed quantitative polym erase chain reaction (qPCR) 
on a panel of cDNA samples from a wide range of normal tissues (Figure 1).5As a positive 
control, we performed qPCR on c DNA from cells of a plasmacytoma that was resected from a 
16
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
patient with advanced MM.5Ninety-three percent of the cells  from the plasmacytoma sample 
were plasma cells as determined by flow cytometry.  The BCMA ex pression of the 
plasmacytoma sample was dramatic ally higher than the BCMA expre ssion of any other tissue 
(Figure 1).  Not surprisingly, B CMA cDNA copies were detected i n several hematologic tissues 
such as blood leukocytes, bone  marrow, spleen, lymph node, and tonsil.  Low levels of BCMA 
cDNA copies were detected in the  samples of testis and trachea.   In addition, low levels of 
BCMA cDNA copies were detected i n most gastrointestinal organs such as duodenum, rectum, 
and stomach (Figure 1).  One possi ble explanation for BCMA expr ession in gastrointestinal 
organs and the trachea was the known presence of plasma cells a nd B cells in tissues such as 
lamina propria and Peyerâ€™s Patches 79,80.
In Figure, 1 actin cDNA copies a nd BCMA cDNA copies were measur ed by qPCR in all of the 
samples, and the results were ex pressed as the number of BCMA c DNA copies per 105actin 
cDNA copies.5

17
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
After demonstrating a very restr icted expression pattern of BCMA  RNA, we carried out an 
assessment of BCMA protein exp ression by immunohistochemistry ( IHC).  As expected, our 
anti-BCMA IHC staining procedure yielded strong staining of BCM A-K562 cells, which 
expressed high levels of BCMA af ter being transduced with the g ene encoding BCMA.  We 
found a lack of BCMA staining wit h NGFR-K562 negative control c ells.5We went on to 
evaluate BCMA protein expres sion in normal human organs.  Excep t for plasma cells, we did not 
detect BCMA protein expression b y the cells of any of the organ s that we stained.  We detected 
plasma cells expressing cell-su rface BCMA in gastrointestinal organs.  BCMA expression by 
normal plasma cells probably acc ounts for the low levels of BCMA RNA detected in these 
organs because we did not detect B CMA expression by any of the other cells in these organs.  
We detected BCMA-expressing pl asma cells in the tonsil.  The or gans assessed by IHC and 
found to lack BCMA expression excep t for plasma cells are shown  in Table 1.5We concluded 
that BCMA expression detected at low levels in some organs by qPCR (Figure 1) was due to 
plasma cells in these organs.
Table 1
adrenal 
bladder bonebreast cerebellum cerebral cortexduodenumeye fallopian tube esophagus stomach small intestine colon rectum heart kidneyliverlungovary pancreas parathyroid pituitary placenta prostate skin spinal cord spleen skeletal muscletestis thymus thyroid trachea cervix uterine endometrium
Organs stained for BCMA by  immunohistochemistry and   
found to lack of BCMA expression except on plasma cells
For a protein to be an appropriate target for CAR-expressing T cells aimed at MM, the protein 
must be expressed on the surface of  MM cells. By flow cytometry of bone marrow samples from 
18
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
patients with MM, we found that  6/10 tested samples uniformly e xpressed high levels of BCMA 
by flow cytometry.  An example of  this flow cytometry staining is shown in Figure 2.
Figure 2
Events
BCMA
As shown in Figure 2, flow cytomet ry for BCMA (solid line) and i sotype-matched control 
staining (dashed line) revealed BCMA expression on the surface of MM cells from a 
plasmacytoma of a patient with MM.5The plot is gated on plasma c ells, which made up 93% of 
the total plasmacytoma cells.  In addition to the flow cytometr y studies, we stained tissue 
sections from plasmacytomas of  3 patients with MM.  In all 3 of  the samples, the neoplastic 
plasma cells expressed cell-surface BCMA.5
1.2.7 Anti-BCMA CAR developmen t and preclinical testing
Due to the expression pattern of BCMA, we reasoned that BCMA would be an appropriate target 
for CAR-expressing T cells.  To further assess the suitability of BCMA as a target for CAR-expressing T cells, we designed an anti-BCMA CAR.  The anti-BCMA CAR contained an scFv derived from one of two mouse an ti-human-BCMA monoclonal antibo dies 
81.   The anti-BCMA 
CAR also contained the hinge and transmembrane regions of the h uman CD8 Dmolecule, the 
signaling moiety of the CD28 cos timulatory molecule, and the si gnaling domains of the CD3 ]
molecule (Figure 3). 
Figure 3
CD28 CD8 hinge+TM CD3] Anti-BCMA scFv 3â€™LTR 5â€™LTR
We also designed a negative-control CAR named SP6.  The SP6 CAR  contained the variable 
regions of the hapten-speci fic SP6 monoclonal antibody 39.  Except for the different variable 
regions, the sequence of the SP6 CAR was identi cal to the seque nce of the anti-BCMA CAR.  
We ligated DNA encoding each of t he CARs that we designed into a gammaretroviral vector that 
has been used in previously in man y clinical trials of T-cell g ene therapies.4,24,26,32After 
transductions, we found high level s of cell surface expression of the anti-BCMA CAR on the 
transduced T cells (Figure 4).
Figure 4
19
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
CD8 CD8CAR+
CAR+Anti-BCMA CAR Untransduced
Figure 4 shows anti-BCMA CAR exp ression on T cells from Donor 1 6 days after transduction 
with gammaretroviruses encoding  the anti-BCMA CAR.  Transductio ns were carried out 2 days 
after the cultures were starte d, so the T cells had been in cul ture for a total of 8 days at the time 
of this analysis.  The plots are gated on live, CD3+lymphocytes.
We also performed a series of i n vitro assays to assess the fun ction of anti-BCMA-CAR-
expressing T cells, and we found that BCMA-CAR-expressing T cel ls exhibit BCMA-specific 
activities including CD107a upreg ulation and cytokine productio n in vitro.  These experiments 
showed that anti-BCMA-CAR-expre ssing T cells are activated in a  BCMA-specific manner.
20
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure5
BCMA-K562                        NGFR-K562Anti-BCMA CAR-transduced
Untransduced
BCMA-K562                       NGFR-K562CD107a
CD107aCD107aCD107aCD8 CD8
CD8 CD8
Figure 5 shows upregulation of CD 107a, which indicates degranulation and correlates with 
cytotoxicity82, when anti-BCMA CAR-expressing T  cells from Donor 1 were cultured with the 
BCMA-expressing cell line BCMA-K562.  CD107a was not upregulate d when anti-BCMA-
CAR-expressing T cells from Donor 1 were cultured for 4 hours w ith the BCMA-negative 
control cell line NGFR-K562.  Untransduced T cells from Donor 1  did not upregulate CD107a 
when cultured with either BCM A-K562 or NGFR-K562.  The plots ar e gated on live CD3+
lymphocytes.  The T cells depicted in Figure 5 are from the sam e cultures as the cells shown in 
Figure 4 and were used in this ex periment on the same day of cu lture as the cells shown in 
Figure 4. 
T cells transduced with the anti- BCMA CAR produced large amount s of IFNJwhen they 
were cultured overnight with the B CMA-expressing cell lines BCM A-K562 and RPMI8226 
(Figure 6).  In contrast, the a nti-BCMA CARs produced only back ground levels of IFN Jwhen 
they were cultured with the BCMA-negative target cell lines NGF R-K562, CCRF-CEM, and 
A549.  The anti-BCMA-CAR-transduced T cells also made minimal I FNJwhen cultured without 
any target cell.  The experiment depicted in Figure 6 consisted of culturing the anti-BCMA-
CAR-transduced T cells with the indicated target cell lines ove rnight and then performing a 
standard IFN Jenzyme-linked immunosorbant assay (ELISA).
21
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure 6
Large fractions of anti-BCMA-CAR- transduced T cells produced th e cytokines IFN J, tumor 
necrosis factor (TNF), and interleukin-2 (IL-2) when cultured w ith the BCMA+target cell 
BCMA-K562 but not when cultured with the BCMA-negative cell lin e NGFR-K562 (Figure 7).  
For the assay described in Figure 7, T cells and target cells w ere cultured together for 6 hours, 
and an intracellular cytokine sta ining assay was performed to d etect the cytokines within the T 
cells as described previously.5The plots shown in Figure 7 are gated on CD3+lymphocytes.
22
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Figure 
7
CD4TNF
CD4IL-2
CD4
 CD4IFNJ
CD4TNF IL-2
CD4IFNJBCMA-K562                          NGFR-K562
BCMA-K562                        NGFR-K562
BCMA-K562                       NGFR-K562
Anti-BCMA-CAR-transduced T cells  also proliferated in a BCMA-spe cific manner.  
Figure 8 shows a carboxyfluorescein diacetate,succinimidyl ester ( CFSE) proliferation assay in 
which anti-BCMA-CAR-transduce d T cells were cultured for 4 days  with either BCMA-K562 
cells or BCMA-negative NGFR-K 562 cells.  CFSE was diluted to a g reater degree, indicating 
more proliferation, when the T cells were cultured with BCMA-K5 62 target cells (solid 
histogram in Figure 8) compare d to when anti-BCMA-CAR T cells w ere cultured with BCMA-
negative NGFR-K562 target cells .  The assay was conducted as de scribed previously.5
Figure 8
23
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Normalized event number
CFSE
We established RPMI8226 human mu ltiple myeloma cell line tumors  in immunodeficient mice.5
We allowed sizable tumors t o develop over 17 to 19 days then we treated the mice with a single 
intravenous infusion of anti-BCMA -CAR-transduced human T cells.   After infusion of anti-
BCMA-CAR T cells, dramatic regressions of all tumors occurred b etween day 6 and day 15 after 
the T cell infusion, and 100% of mi ce receiving anti-BCMA-CAR T  cells were cured (Figures 9 
and 10).5In contrast, tumors continued to i ncrease in size in all mice r eceiving infusions of T 
cells expressing a negative-cont rol CAR designated SP6.  The mi ce receiving infusions of anti-
BCMA-CAR-transduced T cells had no signs of toxicity during thi s experiment.
Figure 9
Anti-BCMA CAR
In the experiments depicted i n Figures 9 and 10, anti-BCMA-CAR T cells were infused on Day 
0, and no other treatments were administered.  In the experiments reported in Figures 9 and 10, 
there were 10 mice in the anti- BCMA CAR and SP6 groups.  There were 7 mice in the untreated 
group.
Figure 10
24
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Myeloma cells from a plasmacytoma  of a patient with MM were spec ifically killed by 
autologous anti-BCMA-CAR-trans duced T cells at low effector :target ratios while autologous T 
cells transduced with the negativ e control CAR SP6 caused only a low level of cytotoxicity  of 
the myeloma cells in a 4-hour cytotoxicity assay (Figure 11).5For all effector: a target ratio, the 
cytotoxicity was determined in dup licate, and the results are di splayed as the mean +/- the 
standard error of the mean.
Figure 11
1.2.8 Rationale for imm unosuppressive chemoth erapy and selection  of lymphocyte-depleting 
chemotherapy regimen
25
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
We plan to administer a conditioni ng chemotherapy regimen of cyclophosphamide and 
fludarabine before infusions of a nti-BCMA-expressing T cells be cause substantial evidence 
demonstrates an enhancement of the anti-malignancy activity of adoptively-transferred T cells 
when chemotherapy or radiother apy are administered before the T  cell infusions.6,8,83In mice, 
administering chemotherapy or radiotherapy prior to infusions o f tumor-antigen-specific T cells 
dramatically enhanced the anti-tu mor efficacy of the transferre d T cells.6,8,25,26,83,84
Administering chemotherapy or radiotherapy enhances adoptive T- cell therapy by multiple 
mechanisms including depletion of  regulatory T cells and elevat ion of T-cell stimulating serum 
cytokines including interleuki n-15 (IL-15) and interleukin-7 (I L-7), and possibly depletion of
myeloid suppressor cells and other mechanisms.6,8,84,85Removal of endogenous â€œcytokine sinksâ€ 
by depleting endogenous T cells  and natural killer cells caused serum levels of important T-cell 
stimulating cytokines such as IL-15 and IL-7 to increase, and i ncreases in T-cell function and 
anti-tumor activity were dependent on IL-15 and IL-7.6Experiments in a murine xenograft 
model showed that regulatory T cells could impair the anti-tumo r efficacy of anti-CD19 CAR T 
cells.86Myeloid suppressor cells have bee n shown to inhibit anti-tumor responses.85
Experiments with a syngeneic murine model sh owed that lymphocyt e-depleting total body 
irradiation (TBI) administered pr ior to infusions of anti-CD19- CAR-transduced T cells was 
required for the T ce lls to cure lymphoma.7In these experiments, some mice received TBI, and 
other mice did not receive TBI.  A ll mice were then challenged with lymphoma and treated with 
syngeneic anti-CD19-CAR T cells .  Mice receiving TBI had a 100% c ure rate and mice not 
receiving TBI had a 0% cure rate.7
Strong suggestive evidence of enh ancement of the activity of ad optively-transferred T cells has 
been generated in humans.30,87,88Very few clinical response s have occurred and very little 
evidence of in vivo activity has  been generated in clinical tri als of anti-CD19-CAR T cells 
administered without lymphocyte- depleting chemotherapy.30,33In contrast, many regressions 
and evidence of long-term B-cell depletion have occurred in cli nical trials in which patients 
received anti-CD19-CAR T cells aft er lymphocyte-depleting chemo therapy.3,4,32,51The 
chemotherapy regimen that best i ncreases the anti-malignancy ef ficacy of CAR-expressing T 
cells is not known, but the most commonly used chemotherapy reg imens that have  been used in 
clinical trials and that convincin gly demonstrate persistence a nd in vivo activity of adoptively 
transferred T cells have inclu ded cyclophosphamide and fludarab ine.3,4,31,32,87,88Both 
cyclophosphamide and fludarabine a re highly effective at deplet ing lymphocytes.87,88One well-
characterized and commonly use d regimen is the combination of 3 00 mg/m2of 
cyclophosphamide administered dail y for 3 days and fludarabine 30 mg/m2administered daily 
for three days on the same days as the cyclophosphamide.89Multiple cycles of this regimen can 
be tolerated by heavily pr etreated le ukemia patients.89
1.2.9 Rationale for dose-escalation
The clinical trial described in t his protocol is planned as a d ose escalation in which the number 
of anti-BCMA-CAR T cells admin istered to patient s will be incre ased with sequential dose 
levels.  The rationa le for conducting a dose-escalation trial o f a cellular therapy is based on two 
main sources of evidence.  First, t he anti-tumor efficacy of ado ptively-transferred T cell 
treatments increases as the dose  of T cells administered to mic e increases.90-92Second, in the 
setting of allogeneic transplanta tion, relapsed malignancy is o ften treated with infusions of 
allogeneic donor lymphocytes (DLIs).93,94The incidence of graft-versus-host disease, which is 
26
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
caused by T cells attacking allogeneic antigens on host tissues , increases as the  dose of T cells 
administered in DLIs increasesâ€™.93,94
1.2.10 Summary of risks a nd potential benefits
This clinical trial i s being performed to evaluate a geneticall y-modified T-cell therapy for 
multiple myeloma, which is an almost always incurable disease.12Only patients with multiple 
myeloma who have progressive or r elapsed myeloma  despite at lea st 3 prior lines of therapy will 
be enrolled. The risks  of the study fall into 3 general categories.  First, chemotherapy that could 
cause cytopenias is part of the  protocol.  As with any chemothe rapy that causes neutropenia and 
thrombocytopenia, this chemothe rapy could cause toxicities such as infections and bleeding. The 
second category of toxicity is c ytokine-release-type toxicities  such as high fevers, hypotension 
and neurological toxicities su ch as delirium, obtundation, myoc lonus, seizures, headache, and 
transient focal neurological to xicities including aphasia and f ocal paresis.  These cytokine-
release-type toxicities have bee n detected in other clinical trials of CAR T cells during the first 2 
weeks after anti-CD19 CAR T cells were infused.4,95In the anti-CD19 CAR trials, these 
toxicities have been transient with toxicities generally resolv ing within 2 days to 2 weeks.  The 
third main category of toxicity i s direct damage to normal tissues by the CAR T cells.  This 
could happen because of unexpect ed expression of BCMA on normal cells or because of 
unexpected cross-reactivity of the  anti-BCMA CAR with proteins other than BCMA in vivo. A 
potential toxicity caused by ant i-BCMA CAR T cells damaging nor mal cells is 
hypogammaglobulinemia due to depl etion of plasma c ells and a sub set of mature B cells.  
Hypogammaglobulinemia has been a c omplication for many patients on clinical trials of anti-
CD19 CAR-expressing T cells.4,32. Hypogammaglobulinemia in the se patients was routinely 
treated with infusions of i ntravenous immunoglobulins.4
The potential benefits to subject s enrolling on this trial incl ude the possibility that the anti-
BCMA-CAR T cells can cause a sig nificant anti-myeloma effect.  Many patients enrolled on 
early trials of anti-CD19 CAR T  cells obtained prolonged comple te remissions of advanced 
malignancies3,4,96, so there is a chance that recip ients of anti-BC MA CAR T cells  could also 
derive a direct benefit from participation in this trial.  Pati ents might also derive a benefit from 
knowing that they are contributin g to the development of new ce llular therapies for cancer.  
Aiding in the development of new therapies might help future pa tients.
2ELIGIBILITY ASSESSMENT AND ENROLLMENT
2.1 ELIGIBILITY CRITERIA
Note: if a patient meets an elig ibility requirement as outlined below, and is enrolled on the 
protocol but then is found to no long er meet the eligibility req uirement after  enrollment but 
before the start of protocol treatment, the treatment will be a borted.
2.1.1 Inclusion Criteria
2.1.1.1 Multiple Myeloma criteria
xClear BCMA expression must be det ected on greater than 50% of ma lignant plasma cells 
from either bone marrow or a plasmacytoma by flow cytometry or 
27
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
immunohistochemistry.  These assays must be performed at the Na tional Institutes of 
Health. It is not required that the specimen used for BCMA deter mination comes from a 
sample that was obtained after the patientâ€™s most recent treatm ent. BCMA expression 
will need to be documented on the majority of malignant plasma cells at some time after 
the original anti-BCMA CAR T- cell infusion in all patients unde rgoing a second anti-
BCMA CAR T-cell infusion.  If paraffin embedded unstained sampl es of bone marrow 
involved with MM or a plasmacytoma are available, these can be shipped to the NIH for 
BCMA staining, otherwise new biopsies will need to be performed  for determination of 
BCMA expression.
xBone marrow plasma cells must make up 30% or less of total bone  marrow cells based on 
a bone marrow biopsy performed within 30 days of the start of p rotocol treatment.
xPatients must have received at least 3 different prior treatment  regimens for multiple 
myeloma
xPatients must have measurable MM as defined by at least one of the criteria below.
Â¾One or more of these abnormalit ies defines measurable disease:
Â¾Serum M-protein greater or  equal to 0.4 g/dl (10 g/l). 
Â¾Urine M-protein greater or equal to 200 mg/24 h.
Â¾Serum free light chain (FLC) ass ay: involved FLC level greater or equal to10 mg/dl 
(100 mg/l) provided serum F LC ratio is abnormal.
Â¾A biopsy-proven plasmacytoma
2.1.1.2 Other inclusion criteria:
xGreater than or equal to 18 years of age and less than or equal  to age 73.
xAble to understand and sign the I nformed Consent Document.
xClinical performance status of ECOG 0-2
xPatients of both genders must be  willing to practice birth control from the time of 
enrollment on this study and for f our months after receiving the  preparative regimen.
xWomen of child bearing potential must have a nega tive pregnancy test because of the 
potentially dangerous effects of the preparative chemotherapy o n the fetus.
xSeronegative for HIV antibody.  ( The experimental treatment bei ng evaluated in this 
protocol depends on an intact immune  system.  Patients who are HIV seropositive can 
have decreased immune -competence and thus are less responsive to the experimental 
treatment and more susceptib le to its toxicities.) 
xSeronegative for hepatitis B antigen, positive hepatitis B test s can be further evaluated by 
confirmatory tests, and if confirmatory tests are negative, the  patient can be enrolled.
28
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xSeronegative for hepatitis C an tibody unless antigen negative.  If hepatitis C antibody test 
is positive, then patients must be  tested for the presence of a ntigen by RT-PCR and be 
HCV RNA negative.
xAbsolute neutrophil count greater than or equal to 1000/mm3without the support of 
filgrastim or other growth factors.  
xPlatelet count greater than or equal to 45,000/mm3without transfusion support 
xHemoglobin greater than 8.0 g/dl.  
xLess than 5% plasma cells in t he peripheral blood leukocytes 
xSerum ALT and AST less or e qual to 2.5 times the upper limit of  the institutional normal.
xSerum creatinine less than or equal to 1.3 mg/dL.
xTotal bilirubin less than or equal to 2.0 mg /dl, except in patie nts with Gilbertâ€™s Syndrome 
who must have a total b ilirubin less than 3.0 mg/dl.
xAt least 14 days must have elapse d since any prior systemic the rapy at the time the 
patient starts the cyclophospha mide and fludarabine conditionin g regimen, and patientsâ€™ 
toxicities must have recovered t o a grade 1 or less (except for  toxicities such as alopecia 
or vitiligo). 
xBecause this protocol require s collection of autologous blood c ells by leukapheresis in 
order to prepare anti-BCMA-CAR T cells, systemic anti-myeloma t herapy including 
systemic corticosteroid steroi d therapy of greater than 5 mg/da y of prednisone or 
equivalent dose of another cor ticosteroid are not allowed withi n 2 weeks prior to the 
required leukapheresis.
xNormal cardiac ejection fractio n (greater than or equal to 50% b y echocardiography) and 
no evidence of hemodynamically sig nificant pericardial effusion as determined by an 
echocardiogram within 6 weeks of t he start of the treatment prot ocol.
xPatients should not take corticos teroids including prednisone, dexamethasone or any 
other corticosteroid for any  purpose at doses higher than 5 mg/d ay of prednisone or 
equivalent dose of another corticosteroid 2 weeks before apheres is and within 2 weeks 
prior to CAR T-cell infusion, a nd at any time after the CAR T c ell infusion.
2.1.2 Exclusion criteria: 
Patients on any anticoa gulants except aspirin are not eligible.
xPatients that require urgent the rapy due to tumor mass effects or spinal cord compression.
xPatients that have active hemolytic anemia.
xPatients with second malignancies in add ition to multiple myelo ma are not eligible if the 
second malignancy has required t reatment within the past 3 year s or is not in complete 
remission. There are two excepti ons to this criterion: successfully treated non-metastatic 
basal cell or squamous c ell skin carcinoma.   
xWomen of child-bearing potential who are pregnant or breastfeed ing because of the 
potentially dangerous effects of t he preparative chemotherapy o n the fetus or infant.
29
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xActive systemic infections (defi ned as infections causing fever s or requiring anti-
microbial treatment), active co agulation disorders or other major uncontrolled medical 
illnesses of the cardiovascular, respiratory, endocrine, renal,  gastrointestinal, 
genitourinary or immune system, history of myocardial infarction , active cardiac 
arrhythmias, active obstructive or restrictive pulmonary diseas e.
xAny form of primary immunodeficiency  (such as Severe Combined I mmunodeficiency 
Disease). 
xSystemic corticostero id steroid therapy of greater than 5 mg/day of prednisone or 
equivalent dose of another cor ticosteroid are not allowed withi n 2 weeks prior to either 
the required leukapheresis or t he initiation of the conditionin g chemotherapy regimen.
xHistory of severe immediate hypersensitivity reaction to any of  the agents used in this 
study.
xHistory of allogeneic stem cell transplantation
xPatients with CNS metastases or s ymptomatic CNS involvement (in cluding cranial 
neuropathies or ma ss lesions and spinal cord compression).
xPatients with active autoimmune s kin diseases such as psoriasis or other active 
autoimmune diseases such as rheumatoid arthritis.
2.2 SCREENING EVALUATION
The following assessments must be completed within 30 days prior to starting the 
chemotherapy conditioning regime n unless otherwise noted (if not , then the evaluation 
must be repeated):
xComplete history and physical e xamination, including, weight an d vital signs, noting in 
detail the exact size and locati on of any lesions that exist. 
xConfirmation of diagnosis of MM by t he NCI Laboratory of Patholo gy and confirmation 
of clear BCMA expression on the m ajority of malignant plasma cel ls from either bone 
marrow or a plasmacytoma by flow cytometry or immunohistochemis try. The sample 
used for this BCMA expression a nalysis can come from any time prior to enrollment on 
the protocol.
xBone marrow aspirate and biopsy specifically ask for BCMA immun ohistochemistry
staining of the bone marrow biopsy .  Order cytogenetics with in terphase FISH and flow 
cytometry on the bone marrow aspirate.  Cytogenetics studies are not required if a written 
report of cytogenetics studies  performed at any time are availa ble from an outside 
institution. The bone marrow biops y must take place at some time after the patientâ€™s 
most recent myeloma treatment. If the patient agrees to future u se of specimens when 
screening bone marrow is obtai ned, reserve one tube of bone mar row aspirate to be sent 
to Fran Hakimâ€™s lab for researc h purposes.  Attention Jeremy Rose, Bldg 10, room 
12C216 contact phone: 301-594 5339. (A bone marrow biopsy must al so be performed 
with in 30 days of starting the pr otocol treatment to assess for  disease burden. See section 
3.1.4 for details.)
30
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xAll patients must have  flow cytometry staining of bone marrow o r plasmacytoma cells 
for BCMA by Dr. Stetler-Stevens onâ€™s lab (NCI Laboratory of Path ology).
xEKG
xMRI of spine and pelvis (only if clinically indicated in patien ts with back pain or pelvic 
pain or a history of plasmacytoma s of spine or pelvic bones are  present) 
xMRI of the brain-within 6 weeks  of protocol treatment start.
xIf necessary to document progressi ve disease obtain a skeletal X-ray survey
xDonor venous assessment
xAntibody screen for Hepatitis B and C; HIV, HTLV-I/II, T. cruzi  (Chagas agent), West 
Nile, and syphilis (RPR)
xCardiac echocardiograph-within 6 w eeks of protocol treatment start.
x(Sodium (Na), Potassi um (K), Chloride (Cl) , Total CO2 (bicarbon ate), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  total (Mg), 
Inorganic Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Prote in, Total CK, Uric Acid)
xCBC with differential and platelet count
xSerum immunofixation electrophoresis
xSerum immunoglobulin free light chains
xGlucose-6-phosphate dehydrogenase (G6PD) deficiency screening
xThyroid panel 
xSerum Cortisol
xÈ•-HCG pregnancy test (serum or  urine) on all women of child-bear ing potential 
2.3 REGISTRATION PROCEDURES
Authorized staff must register an eligible candidate with NCI Ce ntral Registration Office (CRO) 
within 24 hours of signing consen t.  A registration Eligibility  Checklist from the web site 
(http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) must be completed and sent via 
encrypted email to:  NCI Central Registration Office  ncicentralregistration-l@mail.nih.gov .
After confirmation of eligibility at Central Registration Offic e, CRO staff will call pharmacy to 
advise them of the acceptan ce of the patient on the protocol pr ior to the release of any 
investigational agents.  Verif ication of Registration will be f orwarded electronically via e-mail to 
the research team. A recorder is available during non-working hours.
3STUDY IMPLEMENTATION
3.1 STUDY DESIGN
3.1.1 General study plan  
31
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
This protocol is a phase I dose-escalation study of autologous T cells that are genetically 
modified to express an anti-BCMA CAR.
The protocol will enroll patients with multiple myeloma that is  progressive or relapsed despite at 
least 3 prior lines of therapy.  P atients will be e valuated for general health, and multiple 
myeloma staging will be carri ed out.  An assessment of BCMA exp ression will be an important 
part of the eligibility screenin g.  Patients enrolled on the st udy will undergo leukapheresis, and 
anti-BCMA-CAR-expressing T cells  will be generated by transduci ng the patientâ€™s  T cells with a 
gammaretrovirus encoding the anti-BCMA CAR.  During the time of  T-cell preparation, the 
patients will receive a conditioni ng chemotherapy regimen of cy clophosphamide 300 mg/m2
daily for 3 days and fludarabine 30 mg/m2IV daily for 3 days on the same days.  This is an 
extensively-used chemotherapy regimen that can be easily adminis tered on an outpa tient basis.  
Two days after the end of the c onditioning chemotherapy, patien ts will receive a single infusion 
of anti-BCMA-CAR-expressing T cells.  A minimum 9-day hospitali zation will be required after 
the cell infusion to monitor closely for acute toxicities. Patie nts are required to stay within 60 
minutes driving time from the Clinical Center until day 14 afte r the CAR T-cell infusion.
Patients will then be e valuated for toxicit y and multiple myelo ma will be stage d 2 weeks and 1, 
2, 3, 4, 6, 9, and 12 months after the infusion.A small number of subjects may b e eligible for re-enrollment if  a patient is removed from the 
protocol BEFORE receiving any protocol therapy, and would be re quired to meet all eligibility 
criteria at the time of re-enrollment. Patients will be assigne d a new sequential study number for 
the re-enrollment study period. A ny cryopreserved cells produce d from a patient who was 
removed from the study can be use d to treat that patient after re-enrollment. We do not anticipate 
changes in the risk profile for t he initial versus re-enrollmen t.
32
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.1.2 Protocol schema
Leuka pheresis
In vitro generation of 
Anti-BCMA-expressing
T cells (9-11 days)Pretreatment staging
Infusion of recipient with
Anti-BCMA-CAR-expressing T-Cells
(Inpatient for 9-days minimum post 
infusion )
Potential repeat treatments for patients with 
persistent myelomaFollow-up 2 weeks and 1, 2, 3, 4, 6, 9, and 12 
months post-infusion. Then every 6 months 
up to 5 years post-infusion.Outpatient or inpatient 
cyclophosphamide plus fludarabine 
conditioning chemotherapyPatient Baseline evaluation
33
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.1.3 Dose Limiting Toxicity
Dose-limiting toxicities are defined as follows:
oGrade 3 toxicities possibly or probably related to either the a nti-BCMA CAR T 
cells or the fludarabine and cyclophosphamide chemotherapy and l asting more 
than 7 days
oGrade 4 toxicities possibly or pr obably related to the study in terventions
The following specific toxicities will not be dose-limiting tox icities:
oNeutropenia (ANC<500/ PL) lasting 9 days or less
oAnemia (Hgb<8 g/dL) lasting 7 days or less
oGrade 4 thrombocytopenia lasting 25 days or less
oGrade 3 thrombocytopenia
oHypotension requiring treatment  with vasopressors for 72 hours o r less.  The 72
hours is measured from the firs t institution of vasopressors eve n if vasopressors 
are temporarily discontinued and then re-started..
oFever
oAll cytopenias except neutrope nia, anemia, and thrombocytopenia
oAasymptomatic electrolyte dist urbances regardless of grade
3.1.4 Dose EscalationThe trial will be a dose-escalation with 4 dose levels based on t he patientâ€™s actual bodyweight.
As of amendment C, the number of anti-BCMA-CAR-expressing T cel ls transferred for each 
dose level will be as shown in the Dose Escalation Schedule bel ow. for patients in which less 
than 350% of total bone marrow cells are plasma cells. 
Dose Escalation Schedule
Dose Level Dose of IND Agent * 
Level 1 0.3x106CAR+ T cells per kg of recipient bodyweight
Level 2 1.0x106CAR+ T cells per kg of recipient bodyweight 
34
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Each dose level will include a minimum of 3 patients. There will  be a minimum of 9 days 
between the CAR T-cell infusion of a patient and the start of the co nditioning chemotherapy 
regimen for the next patient. Thi s will cause a 14 day delay betw een sequential CAR T-cell 
infusions.
Patients will be enrolled sequentially; therefore, enrollment w ill not proceed to a higher dose 
level until all patients have been treate d in the prior cohort.  If sufficient cells cannot be grown to 
meet the criteria for the assign ed dose level but sufficient cells can be grown to meet the 
requirements of one dose level lower than the assigned dose lev el, the patient w ill be enrolled in 
the appropriate dose level for th e number of cells infused. If a DLT occurs in an additional 
patient entered at a lower dos e due to cell growth limitations,  accrual will continue at this level 
as described in the dose-escalation scheme below.  Accrual will  be halted at the higher level until 
the cohort at the lower level i s complete as described below. If  sufficient cells cannot be 
produced to infuse the number of cells called for by one dose l evel lower than the called for dose 
level, the treatme nt will be aborted.  A s econd attempt will be  made to prepare cells for the 
patient if the patient agrees and if the patient still meets al l eligibility criteria. 
Should none of the first  3 patients treated on a dose level exp erience a DLT accrual can start on 
the next higher dose level after a 14-day delay following CAR T -cell infusion of the third 
patient.  Should 1 of 3 patients expe rience a dose limiting tox icity a particular  dose level,  three 
more patients would be treated a t that dose level to confirm th at no greater than 1/6 patients have 
a DLT prior to proceeding to the  next higher level.  If 1/6 patients have a DLT a t a particular 
dose level, accrual can proceed t o the next higher dose level af ter a 14-day delay following
treatment of the 6thpatient. If a level with 2 or mor e DLTs in 3-6 patients has been  identified, 3 
additional patients w ill be accrued at the next-lowest dose for a total of 6, in order to further 
characterize the safety of t he maximum tolerated dose.  
Starting with Amendment E, only patients with less than 30% bon e marrow plasma cells 
documented on a bone marrow biopsy w ill be enrolled. We have alre ady treated 4 patients on 
dose level 4 (9x106CAR+ T cells/kg).  One of 4 low- dose patients experienced a DLT on dose 
level 4.  If 2 more patients can be  treated on this dose level without a DLT, we will declare dose 
level 4 the maximum tolerate d dose and proceed to treat 8 patients on an expansion cohort as 
described on page 35 of t he protocol. If 2 mor e patients cannot be treated on Dose Level 4 
without a DLT, we will hold disc ussions with the FDA and NCI IR B to ask to proceed with a Level 3 3.0x106CAR+ T cells per kg of recipient bodyweight 
Level 4 9.0x106CAR+ T cells per kg of recipient bodyweight
35
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
lower dose to be determined at that time. Regarding the expansio n cohort of 8 patients, if more 
than 1 patient on this expansion c ohort has a DLT, enrollment o n the expansion cohort will stop.
The maximum tolerated dose is t he dose at which a maximum of 1 of 6 patients has a DLT.  
After a maximum tolerated dose is defined, add itional patients can be treated on this trial.  Up to
8 total additional recipients ca n be treated after an MTD is est ablished. If cell growth limitations 
preclude administration of the maximum tolerated dose, the pati ent will receive as many cells as 
possible up to the maximum toler ated dose. This patient will be replaced in the dose escalation 
by the next enrolled patient. If it proves to be technically imp ossible or impractical to achieve 
the higher dose levels due to cell production constraints and a maximum tolerated dose has not 
been reached, the highest achiev able dose level will be declare d the maximum feasible dose.
Dose escalation will follow the rules outlined in the Table bel ow.
Number of Patients with 
DLT
at a Given Dose LevelEscalation Decision Rule
0 out of 3 Enter up to 3 patients at the next dose level
>2 Dose escalation will be st opped.  This dose level will 
be declared the maximally administered dose 
(highest dose administered).  Up to three (3) additional patients will be entered at the next lowest 
dose level if only 3 patients were treated previously 
at that dose.
1 out of 3 Enter up to 3 more patie nts at this dose level.
xIf 0 of these 3 patients experience DLT, 
proceed to the next dose level.
xIf 1 or more of this group suffer DLT, then 
dose escalation is stopped, and this dose isdeclared the maximally administered dose.  UP to three (3) additi onal patients will be 
entered at the next low est dose level if only 3 
patients were treated p reviously at that dose.
<1 out of 6 at highest dose 
level below the maximally 
administered doseThis is the MTD and is generally the recommended phase 2 dose.  At least 6 patie nts must be entered at 
the recommended phase 2 dose.
3.2 DOSE MODIFICATIONS /DELAY
Other Toxicity:
36
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
oPatients may be removed from further treatment if they have active infections defined as 
infections causing fevers or inf ections requiring anti-microbia l therapy that arise while 
patients are on-study but befor e the CAR T-cell infusion; howev er such patients are 
eligible for treatment if they meet all eligibility criteria af ter the infection resolves.  
oIf a patient experiences a grade  3 or greater toxicity (with th e exception of cytopenias 
including neutropenia, lymphopeni a, anemia, or thrombocytopenia) while on-study 
before the CAR T-cell infusion, t he CAR T-cell infusion must be  delayed until the 
toxicity improves to a grade 2 or less.
3.3 DRUG ADMINISTRATION
3.3.1 Leukapheresis
The patient will underg o a 10-15 liter leukaph eresis (generally , 12 liters will be processed to 
target a yield of 6-10 x109 lymphoc ytes) in the Department of T ransfusion Medicine (DTM) 
Dowling Apheresis Clinic accor ding to DTM standard operating pr ocedures.  The procedure 
requires dual venous access, and takes approximately 3-4 hours to complete.  A central line will 
be placed if peripheral venous  access is not sufficient. 
3.3.2 Anti-BCMA-CAR-expressing T-cell preparationAfter cells are obtained by apher esis, further cell processing to generate anti-BCMA CAR-
expressing T cells will occur i n the DTM according to standard operating procedures (SOPs).
Either freshly-collected cells  or cryopreserved cells can be us ed to initiate the cell-preparation 
process. Peripheral blood mononucl ear cells will be  isolated. Su fficient cells for 3 complete cell 
productions will be retained in t he Department of Transfusion M edicine; the excess cells will be 
sent to the ETIB Preclinical Cor e for cryopreservation at 100 to  200 million PBMC per vial.
Contacts in the ETIB preclinical  core are Fran Hakim and Jeremy  Rose (301-594-5339). The 
anti-CD3 monoclonal antibody OKT3 will be used to stimulate T-cell proliferation. Two and 3
days after the start of the T- cell cultures, the cells will be transduced by exposing them to a 
supernatant containing replica tion-incompetent gammaretroviruse s encoding the anti-BCMA 
CAR.  The cells will continue t o proliferate in culture until the day of infusion.  Anti-BCMA-
CAR T cells will be infused be tween day 8 and day 11 of culture . Ten vials of the infused cells 
will be cryopreserved and stored i n the ETIB preclinical core. E ach vial will contain 20 million 
cells.
Before infusion, the percentage of  T cells expressing the anti- BCMA CAR will be determined by 
flow cytometry, and this percen tage of BCMA+ T cells will be us ed in calculating the total 
number of cells to be i nfused to meet the dose requirements of the dose-escalation plan described 
in 3.1.4.  In addition to flow cytometry, further testing of the  cells will take place prior to 
infusion to evaluate for microbi al contamination, replication-competent retroviruses, and 
viability.  Details of this tes ting can be found in the appropri ate DTM SOPs. When a patient is no 
longer eligible for retreatme nt on this protocol due to meeting  any of the off-study criteria listed 
in section 3.7.2, any remaining cryopreserved p retreatment PBMC collected on thi s protocol will 
be transferred from the Departme nt of Transfusion Medicine to t he Principle Investigator of this 
protocol for storage in the ETIB preclinical core and possible u se in research. 
37
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.3.3 Conditioning chemotherapy a nd anti-BCMA CAR T-cell administration-this can be 
either inpatient or outpatient
3.3.3.1 Overall summary of  the treatment plan
Drug Dose Days
Cyclophosphamide 300 mg/m2IV infusion over 
30 minutes Daily x 3 doses on days -5,
-4, -3
Fludarabine 30 mg/m2IV infusion over 
30 minutes administered 
immediately following the cyclophosphamide on day -5, -4, -3Daily x 3 doses on days -5,
-4, -3
Anti-BCMA CAR T cells Variable. One time dose on day 0
3.3.3.2 Detailed treatment plan
Retreatment decisions will be d ecided on a case-by-case basis t o include discussion with FDA.
Day -5, -4, and -3:  Patients will receive pre-hydration with 1 000 mL 0.9% sodium chloride I.V. 
over 1 to 3 hours. 
Patients will receive a nti-emetics following NIH Clinical Cente r guidelines, but dexamethasone 
will not be administered .  One suggested regimen is ondansetron 16 to 24 mg orally on d ays -5, 
-4, and -3 before chemotherapy (I.V. ondansetron can be substit u t e d ) .     P a t i e n t s  s hould be 
provided with anti-emetics such a s lorazepam and prochlorperazine to use at home.  
Next on days -5, -4, and -3, cyclophosphamide at a dose of 300 m g/m2I.V. will be diluted in 100 
ml 5% dextrose solution and infused over 30 minutes.  After the cyclophosphamide on days -5, -
4, and -3, patients will receive 30 mg/m2I.V. fludarabine in 100 mL 0.9% sodium chloride over 
30 minutes.  Note: in patients with a creatinine clearance of 30- 70 ml/minut e/1.73m2 , the 
daily dose of fludarabine will be reduced by 20%.
Following the fludarabine inf usion, patients will receive 1000 mL 0.9% sodium chloride I.V. 
over 1-2 hours. Furosemide w ill be given if needed.
Days -2 and -1:  No interventions except as needed for general supportive care such as anti-
emetics.  To minimize bladder to xicity, patients should increas e normal oral fluid intake to at 
least 2 L/day.Day 0:  Anti-BCMA CAR T cells will be administered.  Premedicati on for the cell infusion will 
be given approximately 30 minutes prior to the infusion.  The p remedications are acetaminophen 
650 mg orally and diphenhydramin e 12.5 mg IV.  Cells are delive red to the patient care unit 
from the Department of Transfus ion Medicine.  Prior to infusion, the cell product identity label is 
double-checked by two authorized staff (MD or RN), and identifi cation of the product and 
38
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
documentation of administration ar e entered in the patientâ€™s ch art as is done for blood banking 
protocols.  The cells are to be infused intravenously over 20 t o 30 minutes via a central line with 
non-filtered tubing, gently agitating the bag during infusion t o prevent cell clumping.  Cells may 
arrive on the unit in a syringe instead of a bag.  In this case , the cells can be administered to the 
patient by pushing the cells through a free flowing normal sali ne line per nursing SOP, but still 
must be infused over 20-30 minutes.  Details of the infusion pr ocedure are included in section 
13.3.
Days 1 to 9: Mandatory hospitalization for observation and trea tment as necessary. In addition, 
patients are required to stay within 60 minutes driving time fr om the Clinical Center until day 14 
after the CAR T-cell infusion.Guidelines for dealing with toxicities that often occur after C AR T cell infusions including 
hypotension, fever and tachycardia are given in Appendix 5.A CB C will be obtained daily.  If the 
absolute neutrophil count become s less than 500/microliter, fil grastim will be initiated at a dose 
of 300 micrograms daily subcutan eously for patients under 70 kg  in weight and at a dose of 480 
micrograms daily for patients over 70 kg in weight.  Filgrastim will be given daily and then
discontinued as soon as the abso lute neutrophil count recovers to 2000/microliter.
3.3.4 Potential repeat treatmentPatients obtaining any response except progressive disease are potentially eligible for a repeat 
treatments consisting of conditi oning chemotherapy followed by an infusion of anti-BCMA CAR 
T cells.  Retreatment w ill be at least 2 months after the origi nal treatment.  Th e dose of anti-
BCMA CAR T cells administered dur ing repeat treatments will be the dose level currently 
enrolling patients receiving initial CAR T-cell infusions.  The r epeat treatments will include the 
same conditioning chemotherapy as the initial treatment. To be eligible for repeat treatments, patients must have not experienced a DLT with their first 
treatment.  Patients mu st also meet the same eligibility requir ements listed in Section 2.1.
BCMA expression must be documented after the first anti-BCMA CA R infusion and before the 
second BCMA CAR T-cell infusion. The patients must undergo scree ning evaluation as listed in 
Section 2.2except infectious disease serol ogy, and brain MRI are not requi red to be repeated 
unless clinically indicated. In addition, serum will be screened for human anti-mouse antibodies
(HAMA) by ELISA in all patients be ing considered for retreatment, and patients with HAMA 
reactivity that first appears after an initial anti-BCMA T-cell  infusion will not be  eligible for re-
treatment.  Follow-up testing for retreatment will be the same as for the first  treatment. The 
patient maybe re-enrolled on the t he study as a new patient to allow this re-tr eatment and these 
patients will be considerd in the t otal sample size for this study. A maximum of 2 total 
treatments can be administered to any one patient, and at least  2 months must elapse between the 
first treatment and t he second treatment.
3.4 P
ROTOCOL EVALUATION
3.4.1 Baseline evaluations and interventions
The following tests must be completed within 14 days of the star t of the conditioning 
chemotherapy regimen:
xPatients must have a central ve nous access before the time of c ell infusion.  This might 
require placement of a non-valv ed P.I.C.C line or other device.
39
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xPhysical exam with vital signs and oxygen saturation
xCT scan of chest, abdom en, and pelvis or PET scan (only if necess ary for staging)
xSkeletal survey.  Additional s cans and x-rays may be performed if clinically indicated 
based on patientsâ€™ signs and symptoms.
xIf necessary for staging: serum  immunofixation electrophoresis 
x250 microgram cosyntropin stimulati on test if suspicious for adr enal insufficiency based 
on low serum sodium or high serum potassium or hypotension or a  history  of adrenal 
insufficiency or other clinical indications
x24-hour urine collection with imm unofixation electrophoresis tim ed urine, and
creatinine for creatinine clearance calculation
xSerum immunoglobulin free light chains
xAnti CMV antibody titer, HSV ser ology, and EBV panel, T cruzi s erology, toxoplasmosis 
serology (Note: patients who a re known to be positive for any of the above do not need to 
be retested; may be performed w ithin 3 months of chemotherapy s tart date)
xSerum will be sent for measles IgG, Rubella IgG, VZV IgG, and p neumococcal 
antibodies (Ab) 23 serotypes
xBlood will be collected for resea rch purposes.  Draw 12 CPT tube s (8 mL each of blood 
will be collected prior to in itiation of the conditioning chemo therapy regimen. This is a 
total of 96 mL of blood. Some of t his blood will be used for immunology assays and 
some will be used for RCR assays. This blood can be collected o n different days as long 
as a total of 12 CPT tubes are co llected prior to cell initiati on of the chemotherapy.  Send 
to Dr. Fran Hakimâ€™s, Pre-Clinical Core lab; Attention Jeremy Ro se, Bldg 10, room 
12C216 contact phone: 301-594-5339.
xIn addition to the CPT tubes , draw 16 mL of blood to obtain ser um for research purposes 
(2 SST tubes, 8 mL per tube) within 3 days prior to the start o f the chemotherapy.  Send 
to Dr. Fran Hakimâ€™s, Pre-Clinical Core lab; Attention Jeremy Ro se, Bldg 10, room 
12C216 contact phone: 301-594-5339.
The following tests must be com pleted within 7 days of the start  of the conditioning 
chemotherapy regimen:
xTBNK 
xSodium (Na), Potassium (K), Chloride (Cl) , Total CO2 (bicarbonat e), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  total (Mg), 
Inorganic Phosphorus, Alkaline Phosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Protein, T otal CK, Uric Acid (to be repeat ed on  the first day of the 
chemotherapy at the  discretion of the PI)
xE 2-microglobulin 
xSerum quantitative immunoglobulins
xABO typing
40
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xIonized calcium
xCBC with differential and plat elet count(to be repeated on  the first day of the 
chemotherapy at the  discretion of the PI)
xPT/PTT
xUrinalysis; if results are a bnormal, send for urine culture
xÈ•-HCG pregnancy test (serum or  urine) on all women of child-bear ing potential
3.4.2 Studies to be performed during the mandatory 9-day inpatient admission after cell 
infusion
xVital signs including pulse oximetry will be monitored q1h x 4 hours after completion of 
the CAR T cell infusion and every 4 hours otherwise unless othe rwise clinically 
indicated.
xDaily physical exam
xCBC twice a day from day 0 until day 10 with differential every 24 hours. After day 10 
do a CBC with differential daily until discharge.
xTBNK on the day of CAR T-cell in fusion (day 0) and day 7 after in fusion
xChemistries twice a  day starting from day 0 to day 10 .After day 10 do chemistries once a 
day until discharge: (Sodium (Na) , Potassium (K), Chloride (Cl),  Total CO2
(bicarbonate), Creatinine, Glucose, Urea nitrogen (BUN), Albumi n, Calcium total, 
Magnesium total (Mg), Inorganic Phosphorus, Alkaline Phosphatas e, ALT/GPT, 
AST/GOT, Total Bilirubin, Direct B ilirubin, LDH, Total Protein, Uric Acid )
xSerum C-reactive peptide (CRP ) within 7 days of day -5 before ini tiation of 
chemotherapy and daily while hospitalized.
xPT/PTT 7 days after cell infusion
xOther tests will be performe d, as clinically indicated.
xResearch blood:  Every Monday, Wednesday, and Friday during hosp italization, starting 
on the first Monday, Wednesday, or F riday after the day of CAR T-cell infusion and 
lasting up to 14 days after infusi on of anti-BCMA-CAR-transduced T cells, 56 mL of 
patient peripheral blood will be  obtained (6 CPT tubes 8 mL eac h and 1 SST tube 8 mL).  
Attention Jeremy Rose, Bldg  10, room 12C216 contact phone: 301-5 94-5339.
3.4.3 Post-infusion outpatient evaluation
After completion of therapy the p atient will be f ollowed for po tential complications related to 
anti-BCMAâ€“CAR T-cell infusion. The  patient will be seen at the N IH in follow-up to evaluate 
disease status and lat e problems related to anti-BCMA â€“CAR T-cel l infusion at days +14, +30, 
+60, +90, and +120; and at 6, 9, and 12 months after anti-BCMA â€“ CAR T-cell infusion. After 
12 months, the patient will be s een every 6 months up to five y ears. At these times patients will 
have the following tests performed to determine clinical respon se:
41
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
x6 CPT tubes of Research Blood (48 mL) will be collected to obtain blood for 
immunological testing. Attention Jeremy Rose, Bldg 10, room 12C216 contact phone: 301-594-5339.
x1 SST tube (8 mL) of Research B lood will be obtained for serum collection.  Attention 
Jeremy Rose, Bldg 10, room 12C216 contact phone: 301-594-5339.
Note: after the first year of follow-up, research blood will be reduce d to 4 CPT tubes 
(32 mL total) during re quired protocol visits .
xCT scan of chest, abdom en, and pelvis or PET scan at outpatient f ollow-up appointments 
starting 1 month after infusion ( only if a plasmacytoma was det ected before treatment)
xPhysical exam with vital signs and oxygen saturation
x(Sodium (Na), Potassium (K), Ch loride (Cl), Total CO2 (bicarbon ate), Creatinine, 
Glucose, Urea nitrogen (BUN), Albumin, Calcium total, Magnesium  t o t a l  ( M g ) ,  
Inorganic Phosphorus, Alkaline P hosphatase, ALT, AST, Total Bil irubin, Direct 
Bilirubin, LDH, Total Prote in, Total CK, Uric Acid)
xE2-microglobulin
xTBNK
xBlood for serum quantitative immunoglobulins
xIonized calcium
xCBC with differential
xUrinalysis: if results are abnormal, send for urine culture
xSerum immunofixation electrophoresis 
x24-hour urine collection with immunofixation electrophoresis time d urine (can be 
omitted if not needed for staging af ter day 30. This is required f or all patients 
pretreatment and at the day 14 and day 30 follow-up appointments). Serum 
immunoglobulin free light chains
xAt the 2 month follow-up, a bone marrow aspirate and biopsy will b e collected.  Aspirate 
must be sent for flow cytometry t o the lab of Dr. Maryalice Ste tler-Stevenson.  BCMA 
staining must be requested for  the flow cytometry.  BCMA immunohistochemistry should 
also be requested on the bone ma rrow biopsy. This may also be pe rformed at day +30 if 
clinically indicated.
xAt the day +180, day +270, and +1 year time points only, serum will be sent for measles 
IgG, Rubella IgG, VZV IgG, and pne umococcal antibodies (Ab) 23 serotypes
xFor patients with ongoing responses a second bone marrow aspira te and biopsy will be 
performed at the 6-month follo w-up appointment. Aspirate must be  sent for flow 
cytometry to the lab of Dr. M aryalice   Stetler-Stevenson.  BCM A staining must be 
requested for the flo w cytometry.  BCMA immunohistochemistry sh ould also be 
requested on the bone marrow biopsy.
42
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xFor each bone marrow aspirate  performed, send o ne tube of bone marrow aspirate to Fan 
Hakimâ€™s lab for research purpos es.  Attention Jeremy Rose, Bldg  10, room 12C316 
contact phone: 301-594 5339.
xGene-therapy-specific follow-up m ust be carried out as describe d in section 3.6
43
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.5 STUDY CALENDAR
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
Clinical Assessments
History and PE XXXXXXXXXX X
Vital signs, O2 
saturationXXXXXXXXXX X
Height, weight XX
Performance Score XX
Laboratory Assessments
CBC with differential  XXXXXXXXXX X
Sodium, Potassium Chloride, CO2, Creatinine, Glucose, BUN, Albumin, Calcium, Magnesium, Inorganic Phosphorus, Alkaline Phosphatase, ALT, AST, T. Bilirubin, D. Bilirubin, LDH, Total Protein, CK, Uric AcidXXXXXXXXXX X
Serum C-reactive peptide XhXmXm
PT/PTT XhX
Ionized calcium XhXXXXXXX X
Thyroid panel XK
44
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
E2-microglobulin  XhXXXXXXX X
Quantitative 
immunoglobulins XhXXXXXXX X
Anti-CMV, HSV, EBV, t.cruzi,toxoplasma  X
h,j
Antibody screen for 
Hepatitis B and C; HIV, HTLV-I/II, T. cruzi (Chagas agent), West Nile,
and syphilis (RPR)X
TBNK  XhXXXXXXXXX X
G6PD XK
Urinalysis (culture prn)  X XXXXXXX X
24 hr urine with 
immunofixation
electrophoresis timed urineX
hXXfXf Xf
XfXfXfXf
24 hr urine Creatinine ClearanceX
h
ABO typing Xh
Serum immunoglobulin free light chainsX XXXXXXX X
45
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
Serum immunofixation
electrophoresisX XXXXXXX X
Radiological Assessments
Skeletal Survey X
CT chest, abdomen, pelvis
f XhXiXXXXXX X
PET fXhXiXXXXXX X
Brain MRI X
Spine and Pelvis MRI eX
Other Specific 
Assessments
Serum Cortisol Xk
250 microgramcosyntropin test
c Xh
EKG, echocardiogram X
RCRXX   XX  Xg
Central Venous catheter placement  X
Donor Venous AssessmentX
Response Evaluation
Bone marrow aspirate/biopsy
d XXlXXe
46
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Follow up
Proceduresa
Screening/
BaselinePre-cell 
infusion
/D a y  0Day 
+7bDay+14 
and  
Day+30
(+/- 5
days)Day 
+60
(+/- 7
days)Day 
+90
(+/- 7
days)Day 
+120
(+/- 10
days)Day 
+180
(+/- 14
days)Day 
+270
(+/- 14
days)Day 
+365
(+/- 30
days)Every 6 
month
after day 
365(+/-
30 days)
up to 5 
years
Research Blood XX  XXXXXXX X
Adverse EventsX XXXXXXXX X
Concomitant Medications XX  XXXXXXXX X
Measles IgG, Rubella IgG, 
VZV IgG, Pneumococcal antibodies 23 serotypesX
hXXX
asee section 2.2and section 3.3.1 for details
bsee section 3.4.2 for details of testing during hospitalization
conly if cortisol<18 mg/dL or clinical suspicion of adrenal insu fficiency
dbone marrow biopsy will include flow cytometry, BCMA expression , cytogenetics, amyloid staining, and molecular studies of each  sample.
eonly if clinically indicated
fif useful for staging
gonly at 2, 3, 4, 5 year point, see section 3.6for details
honly at baseline
ionly D+30, no CTs or PETs indicated at D+14
jPatients who are known to be positive for any of these tests do  not need to be retested; may be performed within 3 months of c hemotherapy start 
date
konly at Screening
lonly Day  30 if clinically indicated
mDone Daily during hositalization
47
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
3.6 GENE-THERAPY -SPECIFIC FOLLOW -UP
xLong-term follow up of patients re ceiving gene transfer is requi red by the FDA and must 
continue even after the patient com es off the study. Physical exam inations will be 
performed and documented annually fo r 5 years following cell in fusion to evaluate long-
term safety.  After 5 years, h ealth status data will be obtaine d from surviving patients via 
telephone contact or mailed ques tionnaires for 10 additional ye ars for a total of 15 years 
after cell infusion.  Blood will n eed to be collected at least annually for long-term follow-
up of gene therapy .
xPersistence of CAR transduced c ells will be ass essed by quantit ative PCR and/or flow 
cytometry at 1, 2, 3, 4, 6 and 12 months after cell infusion, or  until CAR-expressing cells 
are no longer detectable.  If an y patient shows a high level of  persistence of CAR gene 
transduced cells or an increasing population of CAR gene transd uced T cells at month 6 
or later (by FACS staining or qP CR), the previously archived sa mples will be subjected 
to techniques that would allow th e identification of predominant clonal populations of  
transduced cells.
xPatientsâ€™ blood samples will be obt ained and undergo analysis fo r detection of replication 
competent retroviruses (RCR) by PCR prior to cell infusion and at 3, 6, and 12 months 
post cell administration.  Blood s amples will be archived annua lly thereafter if all 
previous testing has been negativ e with a brief clinical histor y.
3.7 CRITERIA FOR REMOVAL FROM PROTOCOL THERAPY AND OFF STUDY CRITERIA
Prior to documenting removal from study, effort must be made to  have all subjects complete a 
safety visit approxima tely 30 days following the last dose of s tudy therapy.
3.7.1 Criteria for removal from protocol therapy
Note that the treatment consists  of a conditioning chemotherapy  regimen followed by a T-cell 
infusion, so off-treatment criteri a mainly apply to eligibility  for potential repeat treatments and 
cancellation of cell infusion for t oxicity arising during the c onditioning chemotherapy. Patients 
will be taken off treatme nt for the following:
xGreater than grade 3 toxicity a ttributable to anti-BCMA CAR T cells makes patients
ineligible for repeat treatments.
xThe patient no longer meets the e ligibility criteria for the protocol after enrolling but 
before start of the chemotherap y conditioning regimen.  If the reason that the patient is 
not eligible can be rapidly res olved within 2 weeks, the treatment can proceed if not, the 
patient will be off-study.
xThe patient receives any other treatment for multiple myeloma e xcept bisphosphonates 
and repeat treatment on this pr otocol.  Bisphosphonates are allowed when administered to 
prevent osteopenia more than 2 m onths after the anti-BCMA-CAR T-c ell infusion.  If a 
patient receives corticosteroid s in doses greater than 5 mg/day  of prednisone or an 
equivalent dose of another corticosteroid, the patient will be off-treatment.
48
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xGeneral or specific changes in  the patientâ€™s c ondition render t he patient unacceptable for 
further treatment on this study in the judgment of the investig ator.
xParticipant requests to be w ithdrawn from active therapy
xInvestigator discretion
xPositive pregnancy test
3.7.2 Off-Study Criteria
Patients will be taken off study for the following:
x The patient voluntarily withdraws
x There is significant patient noncompliance
x Death
x PI decision to end this study 
x The patient no longer meets the e ligibility criteria for the pr otocol after enrolling but 
before start of the chemoth erapy conditioning regimen.
x Development of progressive or relapsed multiple myeloma after an ti-BCMA CAR T 
cell infusion in patients not desiring or not eligible for re-trea tment on this protocol.
x The patient receives any anti-m yeloma therapy except bisphospho nates.
Bisphosphonates are allowed 2 months  or more after the CAR T-ce ll infusion.
x Taking corticosteroids for any reason after CAR T-cell infusion i n a total cumulative 
dose of more than 30 mg of p rednisone or equivalent
Note: Patients must be followe d until all adverse events have r esolved to grade 2 or less with the 
exception of lymphopenia and alopeci a.  If an adverse event is not expected to resolve to grade 2 
or less this will be noted in the  patient medical record and th e patient will be taken off study. In 
addition, all patients mu st be followed for the gene therapy sp ecific follow up as outlined in 
section 3.6prior to being removed from study.
3.7.3 Off Protocol Therapy and Off-Study ProcedureAuthorized staff must notify Cent ral Registration Office (CRO) when a subject is taken off
protocol therapy and when a subj ect is taken off-study. A Participant Status Update Form from 
the web site (http://home.ccr.cancer.gov/intra/eligibility/welcome.htm ) main page must be 
completed and sent via encrypted e mail to:  NCI Central Registr ation Office  
ncicentralregistration-l@mail.nih.gov.
4CONCOMITANT MEDICATIONS/MEASURES
4.1 ANTIBIOTIC PROPHYLAXIS
xPatients with a CD4 T-cell c ount less than 200 will be maintain ed on pneumocystis 
prophylaxis with trimethoprim-su lfamethoxazole 1 double-strengt h tablet every Monday-
49
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Wednesday-Friday. If patients cannot tolerate trimethoprim sulf amethoxazole, an 
alternative pneumocystis  prophylaxis will be used.
xPatients with serum IgG level  less than 400 mg/dL will receive intravenous 
immunoglobulin replacement as need ed to maintain an IgG level a bove 400 mg/dL, if the 
patient has serious bacterial infections.  An example of an int ravenous immunoglobulin 
infusion to be used for this pur pose would be Gammunex 500 mg/kg  given as a single 
dose.  Intravenous immunoglobuli n infusions should be preceded b y premedication with 
diphenhydramine and acetami nophen, and rate of infusion should be started at low rates 
and escalated in a step-wise manner.
xEmpiric Bacterial Antibiotics
xNeutropenic patients will star t on broad spectrum antibiotics w ith a first fever of 38.30C 
or greater or two fevers of 38.0 separated by at least 1 hour a nd concomitant ANC < 
500/ml. 
xAminoglycosides will be avoided unl ess clear evidence of sepsis .
4.2 BLOOD PRODUCT SUPPORT
xLeukocyte filters will be utiliz ed for all blood and platelet transfusions with the exception 
of the CAR-transduced T cell infusions to decrease sensitizatio n to transfused WBC and 
decrease the risk of CMV infection.
xPatients who are seronegative for CMV should receive CMV-negati ve blood products 
whenever possible.
xUsing daily CBCâ€™s as a guide, the patient will receive platelet s and packed red blood cells 
(PRBCâ€™s) as needed.  Attempts w ill be made to keep Hgb >8.0 gm/ dl, and platelets 
>10,000/mm3.  All blood products wit h the exception of the CAR- transduced T cells will 
be irradiated.  Leukocyte filte rs will be utilized for all PRBC  and platelet transfusions to 
decrease sensitization to trans fused WBCâ€™s and decrease the ris k of CMV infection.
4.3 ANTI-EMETICS
Anti-emetics will follow NIH Clinical Center Guidelines (except that corticosteroids will be 
avoided).
4.4 GRANULOCYTE COLONY -STIMULATING FACTOR
A CBC will be obtained daily while  the patient is inpatient.  If  the absolute neutrophil count
becomes less than 500/microliter, Filgrastim will be initiated a t a dose of 300 mic rograms daily 
for patients under 70 kg in weigh t and a dose of 480 micrograms daily for patients over 70 kg in 
weight only in patients with absol ute neutrophil counts less th an 500/microliter.  F ilgrastim will 
be discontinued as soon as the absolute neutrophil count recove rs to 1500/microliter.
4.5 AVOIDANCE OF CORTICOSTEROIDS
Patients should not take corticos teroids including prednisone, dexamethasone or any other 
corticosteroid at a dose equiva lent to 5 mg/day or more of pred nisone for any purpose without 
approval of the Princ iple Investigator.
50
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
4.6 GUIDELINES FOR MANAGEMENT OF COMM ON ACUTE TOXICITIES THAT OCCUR AFTER 
CAR T CELL INFUSIONS
These are guidelines only. It i s understood that treatment of th ese toxicities must be 
individualized for eac h patient.  Not following the exact recom mendations in Section 13.3 is not 
a protocol deviation.
5BIOSPECIMEN COLLECTION
Bio specimen collection on this  protocol will consist of blood d raws and acquisition of bone 
marrow aspirates and possible biops ies of plasmacytomas for res earch purposes.
5.1 CORRELATIVE STUDIES FOR RESEARCH
5.1.1 Biospecimen collection before  the start of the conditionin g chemotherapy:
xOne heparinized syringe containi ng 5 to 8 mL of bone marrow aspir ate to be sent to Fran 
Hakimâ€™s lab.  Attention Jeremy Rose, Bldg 10, room 12C316 conta ct phone: 301-594
5339.It will be used in functional assays to see if anti-BCMA-CAR T cells can recognize 
the patientâ€™s multiple myeloma cells.
xBlood will be collected for res earch purposes.  A total of 12 CP T tubes (8 mL each of 
blood will be collected prior t o initiation of the conditioning  chemotherapy regimen. This 
is a total of 96 mL of blood. Some of this blood will be used for immunology assays and 
some will be used for RCR assays. This blood can be collected o n different days as long 
as a total of 12 CPT tubes are collected prior to the start of t he chemotherapy and within 
14 days of the start of the chemo therapy.  Send to Dr. Fran Haki mâ€™s, Pre-Clinical Core 
lab; Attention Jeremy Rose , Bldg 10, room 12C216 contact phone:  301-594-5339.
x16 mL of blood will be drawn to obt ain serum for research purpos es (2 SST tubes, 8 mL 
per tube) within 14 days prior to t he start of the chemotherapy .  Send to Dr. Fran 
Hakimâ€™s, Pre-Clinical Core lab; Attention Jeremy Rose, Bldg 10, room 12C216 contact phone: 301-594-5339.
xAn apheresis is required to obtai n cells used to prepare the an ti-BCMA CAR T cells that 
are administered on this protocol . After sufficient cells are p rocessed for all possible
clinical needs, the left over a pheresis cells can be cryopreser ved for research use. Note 
that these cells would simply be  discarded if not used for rese arch.
xSpecimens will be cryopreserved and assays will be performed re trospectively.
5.1.2 Biospecimen collection after a nti-BCMA-CAR T-cell infusion  during the required 
hospitalization
Every Monday, Wednesday, and Friday during hospitalization, sta rting on the first Monday, 
Wednesday, or Friday after the CAR T-cell infusion and lasting u p until 14 days after infusion of 
anti-BCMA-CAR-transduced T cells , 56 mL of patient peripheral b lood will be obtained (6 CPT 
tubes 8 mL each and 1 SST tube 8 mL). Attention Jeremy Rose, Bldg 10, room 12C216 contact phone: 301-594-5339.
51
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Additional research blood may be collected at any time during t he clinical course at the 
discretion of the PI (within the volume restriction limits) allow ing for the research studies 
already outlined in this protocol to be performed at the time of an unanticipated clinical event, if 
necessary to address the objectives of the study.
5.1.3 Biospecimen collection dur ing outpatient follow-up
xPatients will retur n for outpatient fo llow-up clinic visits 2 w eeks, 1 month, 2  months, 3 
months, 4 months, 6 months, 9 mont hs and 12 months after the an ti-BCMA- CAR T-cell 
infusion. After the 12-month fo llow-up appointment patients will return for follow-up
every 6 months.  The specimens listed below will be performed at  each outpatient clinic 
visit during the first year of follow up.
Â¾6 CPT tubes of Research Blood ( 48 mL) will be collected to obtain blood for 
immunological testing. Attention Jeremy Rose, Bldg 10, room 12C216 contact 
phone: 301-594-5339.
Â¾1 SST tube (8 mL) of Research B lood will be obtained for serum collection.  
Attention Jeremy Rose, Bldg 10, room 12C316 contact phone: 301- 594-5339.
After 1 year research blood col lected will be reduced to 4 CPT tubes at each visit.
xAt the 2 month follow-up only, bone marrow aspirate and biopsy will be performed and 
the aspirate will be cryopreserved.  
xOnly for patients with ongoing  responses, a second bone marrow aspirate and biopsy will 
be performed at the 6-month fo llow-up appointment , and the aspi rate will be 
cryopreserved.
5.1.4 Immunological Testing
xT-cell assays: Direct immunologi cal monitoring will consist of quantifying CD3+ T cells 
that express the anti-BCMA CAR by quantitative PCR, and/or by flo w cytometry.  These 
assays will be performed to measur e the persistence and estimat e the proliferation of the 
infused CAR+ T cells.  A quantitative PCR assay or a flow cytome try assay will be used 
to quantitate CAR+ T cells at a ll post-infusion time-points up to at least 3 to 6 months 
after infusion, and CAR+ T cell analysis will continue until the CAR+ T cell level drops 
to undetectable levels unless a stable low level of CAR+ T cell s is present at more than a 
year after infusion.  The absolute number of CAR+ PBMC will be estimated by 
multiplying the percentage of CA R+ PBMC by the absolute number of lymphocytes plus 
monoctyes per microliter of bl ood.  Ex vivo immunological assay s will be used to 
measure the BCMA-specific func tional activity of the CAR+ T cells and will consist of 
assays such as intracellular cy tokine staining and anti-CD107a degranulation assays. 
Immunological assays will be sta ndardized by the inclusion of p re-infusion recipient 
PBMC and in some cases an aliquot of  the engineered T cells cry opreserved at the time 
of infusion. 
xSerum cytokine levels will als o be measured by enzyme-linked im mune sorbent assays.   
52
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xGene expression studies will be performed on patient multiple m yeloma cells and on the 
infusion CAR T cells of each p atient.  Methods us ed will be eit her Nanostring and/or 
RNAseq (RNA sequencing).
xPatientsâ€™ blood samples will be obt ained and undergo analysis f or detection of replication 
competent retroviruses (RCR) by PCR prior to cell infusion  and at 3 and 6 months, 
and at one year post cell administration .  Blood samples will be  archived annually
thereafter if all previous testing has been negative with a bri ef clinical history. If a patient 
dies or develops neoplasms during this trial, efforts will be m ade to assay a biopsy 
sample for RCR. If any post-treatment samples are positive, fur ther analysis of the RCR 
and more extensive patient f ollow-up will be undertaken, in consultation with the FDA.   
RCR PCR assays detect the Gibbon Ape Leukemia Virus (GALV) envelop gene and are 
performed under contract by the National Gene Vector Laboratory  at Indiana University  
The results of these tests are m aintained by the contractor per forming the RCR tests and 
by the ETIB research team.
xDue to nature of these studies, it is expected that expansion o f specific T-cell clones will 
be observed as T-cell proliferat e in response to the targeted a ntigen.  Therefore, care will 
be taken to track T-cell persistence, but presence of an oligoc lonal T cell population does 
not indicate an insertional mutagenesis event.  If any patient shows a high level of 
persistence of CAR gene trans duced cells or an increasing population of CAR gene 
transduced T cells at month 6 or l ater (by FACS staining or qPCR), the previously 
archived samples will be subject ed to techniques that would allow the identification of 
predominant clonal populations  of  transduced cells.  Such tech niques may include T cell 
cloning or LAM-PCR.  If a predo minant or monoclonal T cell clon e derived from CAR 
gene transduced cells is iden tified during the follow-up, the i ntegration site and sequence 
will be identified and subsequently analyzed against human geno me database to 
determine whether the sequences are associated with any known h uman cancers.  If a 
predominant integra tion site is observed, the T cell cloning or  LAM-PCR test will be 
used at an interval of no more t han three months after the first observation to see if the 
clone persists or is transient.  In all instances where monoclo nality is persistent and 
particularly in instances where  there is expansion of the clone , regardless of whether or 
not the sequence is known to be a ssociated with a known human ca ncer, the subject 
should be monitored closely for s igns of malignancy, so that tr eatment, if available, may 
be initiated early.
5.1.5 Additional biopsies and additional blood draws
Patients might be ask ed to undergo biopsies or additional blood  draws for research purposes. 
Additional blood draws might be necessary to investigate T cell  responses and serum cytokine 
levels in cases of clinical eve nts such as rapid regressions of  malignancy or t oxicity.  These 
research biopsies are optional and patients can p articipate in this trial whether or not they agree 
to undergo biopsies for researc h purposes.  These biopsies will only be performed if minimal 
morbidity is expected based on the  procedure performed and the granulocyte and platelet count.  
Biopsy tissue will be processed i n the NIH Department of Pathol ogy. Studies will be performed 
to evaluate the antigen expression by the tumor and to evaluate  the reactivity of lymphocyte from 
these biopsies. 
In addition the pr esence of transduced cells ma y be quantitated.
53
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
5.1.6 Future studies 
Blood and tissue specimens collected in the course of this rese arch project may be banked and 
used in the future to investigat e new scientific questions rela ted to this study the patient provides 
consent for this. However, this research may only be done if the risks of the new questions were 
covered in the consent document. If new risks are associated wi th the research (e.g. analysis of 
germ line genetic mutations) a pr otocol amendment will be require d and informed consent will 
be obtained from all research s ubjects to whom these new studie s and risks pertain.
5.2 SAMPLE STORAGE ,TRACKING AND DISPOSITION
5.2.1 Storage/Tracking in the Pr eclinical Development and Clinic al Monitoring Facility 
(PDCMF)
xSamples will be ordere d in CRIS and tracked thr ough Clinical Trial Data Management 
system.  Should a CRIS screen not b e available,the CRIS downtim e procedures will be 
followed.  Samples will not be sen t outside NIH without IRB notification and an 
executed MTA. 
xPatient blood and tissue samples, c ollected for the purpose of research under IRB 
approved protocols of the Exper imental Transplantation and Immu nology Branch, may 
be archived by the ETIB Preclin ical Development and Clinical Monitoring Facility 
(PDCMF). All data associated wit h archived clinical research sam ples is entered into the 
ETIB PDCMFâ€™s Microsoft Excel da tabases on frozen cells and serum . These databases 
are stored on the NCI group drive in the ETIB â€˜PRECLINSERVICEâ€™ f older. Access to 
this folder is limited to PDCMF staff and ETIB clinical staff, re quiring individual login 
and password. All staff in the PDC MF laboratory receive annually  updated NIH/CIT 
training and maintain standa rds of computer security.
xThe data recorded for each sample  includes the patient ID, tria l name/protocol number, 
date drawn, treatment c ycle/post-transpla nt time point, cell so urce (e.g. peripheral blood, 
marrow,) as well as box and freez er location. Patient demograph ics that correlate 
treatment outcomes and therapies  with the samples can be obtain ed only through the 
NCI/ETIB clinical records. As of January 2007, all newly receiv ed samples receive a 
unique bar code number, which is included in the sample record i n the PDCMF database. 
Only this bar code is recorde d on the sample vial and the vials will not be traceable back 
to patients without authorized access to the  PDCMF database. All  non-coded samples 
previously archived will be str ipped of identifiers prior to distribution for any use other 
than as a primary objective of t he protocol under which they were collected.
xSamples are stored in freezers .  . All samples will be labeled solely with a bar code 
(which includes the date, and s erially determin ed individual sa mple identifier). The key 
will be available to a  restricted number of E TIB investigators and associate investigators 
on the protocol. Coded samples will be stored frozen at -20Â°, -8 0Â° or liquid nitrogen 
vapor phase to -180 C acc ording to the stability requirements in a single location under 
the restricted control of the PDCM Facility of ETIB.
xAccess to samples from a protocol for research purposes will be  by permission of the 
Principal Investigator of that protocol in order to be used (1) for research purposes 
associated with protocol objectives for which the samples were collected, or (2) for a new 
54
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
research activity following sub mission and IRB approval of a ne w protocol and consent, 
or (3) for use only as unlinke d or coded samples under the OHSR P Exemption Form 
guidelines stipulating that the activity is exempt from IRB rev iew. Unused samples must 
be returned to the PDCMF laboratory. Samples, and associated dat a, will be stored 
permanently unless the patient w ithdraws consent. If researcher s have samples remaining 
once they have completed all studies associated with the protoc ol, they must be returned 
to the PDCMF laboratory.
xThese freezers are located onsite at the Preclinical Service la boratory (12C216) (-85Â° 
freezer) or in ETIB common equipment space (CRC/3-3273).
5.2.2 Protocol Completion/Sample Destruction 
xOnce research objectives for the  protocol are achieved, researc hers can request access to 
remaining samples, providing t hey have both approval of the Pri ncipal Investigator of the 
original protocol under which the  samples or data were collecte d and either an IRB 
approved protocol and pa tient consent or an OHSRP exemption ind icating that the 
activity is exempt from IRB review.
xThe PDCMF staff will report to the Principal Investigators any d estroyed samples, if 
samples become unsalvageable because of environmental factors ( ex. broken freezer or 
lack of dry ice in a shipping container), lost in transit betwe en facilities or misplaced by a 
researcher. 
xThe PI will report destroyed samples to the IRB if samples beco me unsalvageable 
because of environmental fact ors (ex. broken freeze r or lack of  dry ice in a shipping 
container) or if a patient withdraws consent. Samples will also  be reported as lost if they 
are lost in transit between facilities or misplaced by a researcher.  Freezer problems, lost 
samples or other problems associ ated with samples will also be reported to the IRB, the 
NCI Clinical Director, an d the office of the CCR, NCI.
5.2.3 Samples for Genetic /Genomic Analysis
Samples will use for ge ne expression analysi s will be RNAseq and/ or NanostringTM.
These studies will be used to dete rmine gene expression in mult iple myeloma cells and 
infusion CAR T cells.  The purpose of these studies is to asses s gene expression at the 
RNA level not to study germline mutations.
5.2.3.1 Description of the scope o f genetic/geno mic analysis
RNAseq and/or NanostringTMwill be used to determin e gene expression i n multiple myeloma 
cells and infusion CAR T cells.  T he purpose of these studies i s to assess gene expression at the 
RNA level not to study germline mu tations. One pur pose of these studies is to determine if 
different levels of gene expre ssion in malignant  cells are asso ciated with response to CAR T-cell 
therapy.  Another purpose of these  studies is to determine if d ifferent levels of  gene expression in 
infusion CAR T cells are associa ted with anti-malignancy respon ses caused by CAR T cells or 
persistence of CAR T cells.
55
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
5.2.3.2 Certificate of  Confidentiality 
As part of study efforts to provide confidentiality of subject information, this study has obtained 
a Certificate of Confidentiality, which helps to protect person ally identifiable research 
information. The Certificate of  Confidentiality allows investig ators on this trial to refuse to 
disclose identifying information related to the research partic ipants, should such disclosure have 
adverse consequences for subjects or damage their financial sta nding, employability, insurability 
or reputation. The informed cons ent includes the appropriate co verage and restrictions of the 
Certificate of Confidentiality.
5.2.3.3 Management of ResultsThe analyses that we perform in our laboratory are for research purposes only; they are not 
nearly as sensitive as the tests that are performed in a labora tory that is certified to perform 
genetic testing. Changes that we observe unrelated to our resea rch may or may not be valid. 
Therefore, we do not plan to inform participants of the results  of testing on the tissue and blood 
that is performed in our research lab. However, subjects will b e contacted if a clinically 
actionable gene variant is disc overed. Clinically actionable fi ndings for the purpose of this study 
are defined as disorders appearing in the American College of M edical Genetics and Genomics 
recommendations for the return of incidental findings that is c urrent at the time of primary 
analysis. (A list of current guidelines is maintained on the CC R intranet: 
https://ccrod.cancer.gov/confluence/display/CCRCRO/Incidental+F indings+Lists) Subjects who 
still remain on the study will be  contacted at this time with a  request to provide a blood sample to 
be sent to a CLIA certified laboratory. The CLIA testing may be  funded by the PI or the CCR. If 
the research findings are veri fied in the CLIA certified lab, t he subject will be referred to the NCI 
Genetics Branch for genetic couns eling on the implications of t he results. Subjects that do not 
wish to return to the NCI will be referred to a local genetics health care provider (at their 
expense).This is the only time during the c ourse of the study that incidental findings will be returned. No 
interrogations regarding clinical ly actionable findings will be made after the primary analysis. 
Note: Subjects must remain on the study in order to maintain up  to date contact information and 
to have results returned. Subject s opting for voluntary withdra wal from the study are to be 
informed at the time that results cannot be returned once this has been done.
6DATA COLLECTION AND EVALUATION 
6.1 D
ATA COLLECTION
Data will be prospectively collected and entered in real time i nto the Cancer Center Clinical Data 
System database (NCI C3D database) (information at http://ccrtrials.nci.nih.gov ). It is expected 
that clinical data be entered into C3D no later than after 10 b usiness days of the occurrence. The 
NCI PI and research nurse will ha ve access to these data via we b access.
The medical record will maintain complete records on each patie nt including any pertinent 
supplementary information obtaine d from outside laboratories, o utside hospitals, radiology 
reports, laboratory reports, or o t h e r  p a t i e n t  r e c o r d s .  T h e  N C I  C3D will serve as the primary 
source from which all research  analyses will be performed.  
56
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Data collection will include the eligibility criteria checklist , patient history, specialty forms for 
pathology, radiology, toxicity monitoring, and relapse data and  an off-study summary sheet, 
including a final assessment by the treating physician. After p atients are seen in clinic at each 
scheduled follow up, the datab ase will be updated in real-time. 
All data obtained during the conduc t of the protocol will be ke pt in secure network drives or in 
approved alternative sites that c omply with NIH security standa rds. Primary and final analyzed 
data will have identif iers so that research data can be attribu ted to an individual human subject 
participant.
End of study procedures: Data will be stored according t o HHS , FDA regulations and NIH 
Intramural Records Retenti on Schedule as applicable. 
Loss or destruction of data: Should we become aware that a major breach in our plan to protec t 
subject confidentiality and trial  data has occurred, the IRB wi ll be notified. 
6.1.1 Adverse event recording:
xGrade 1 adverse events will not be recorded.
xGrade 2 adverse events that will be recorded:
a. Unexpected events that are possibly, probably, or definitely r elated to the 
research.
b. Expected events that are probably or definitely related to the  study interventions
will be recorded only for the first year after the infusion..
c. All Infections proven by culture , PCR, antigen detection or ot her laboratory 
methods will be recorded for the f irst year after infusion regard less of attribution.
d. Any serious events that are deem ed clinically significant by th e PI
xAll grade 3, 4, and 5 adverse even ts will be recorded regardless  of attribution.
6.2 GENOMIC DATA SHARING PLAN
Unlinked genomic data w ill be deposited in the  database of geno types and phenotypes (dbGaP) 
in compliance with the NIH G enomic Data Sharing Policy.
6.3 RESPONSE CRITERIA
Responses will be categorized by using the International Unifor m Response Criteria for Multiple 
myeloma.15Multiple myeloma staging will be conducted at the 2 week follow -up appointment 
and at each subsequent follow-up appointment.  T he appropriate staging studies will need to be 
determined for each patient becau se of the variability in multi ple myeloma.   
6.3.1 Important Considerations on response criteria
xResponse criteria for all categor ies and subcategories of respo nse except CR and sCR are 
applicable only to patients who ha ve â€˜measurableâ€™ disease by at least one of the three 
measurements as defined below
xAll responses must be confirme d to be stable in two evaluations made at any time.
6.3.1.1 Definition of measurable disease
57
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Any one or combination of these  abnormalities defines measurabl e disease:
xBefore amendment E: Serum M-pro tein greater or equal to 1 g/dl (10 g/l). 
xAfter amendment E: S erum M-protein greater or equal to 0.4 g/dl ( 10 g/l). 
xUrine M-protein greater or equal to 200 mg/24 h.
xSerum FLC assay: involved FLC level greater or equal to10 mg/dl  (100 mg/l) provided 
serum FLC ratio is abnormal.
xPresence of a biopsy-proven plasmacytoma
6.3.1.2 Laboratory tests for measurement of M-protein
xSerum M-protein level is quan titated using densitometry on SPEP  except in cases where 
the SPEP is felt to be  unreliable such as i n patients with IgA monoclonal proteins 
migrating in the beta region.  If  SPEP is not ava ilable or felt  to be unreliable (e.g., in 
some cases of IgA myeloma) fo r routine M-protein quantitation during therapy, then 
quantitative immunoglobulin levels on nephelometry or urbidomet ry can be accepted.  
However, this must be explicitl y reported, and only nephelometry can be used for that 
patient to assess res ponse and SPEP and nephe lometric values ca nnot be used 
interchangeably.
xUrine M-protein measurement is estimated using 24-h UPEP only.  (Random or 24 h 
urine tests measuring kappa and l ambda light chain levels are n ot reliable and are not 
recommended)
6.3.1.3 Suggested follow-up t o meet response criteria 
xPatients with measurable diseas e by both SPEP and UPEP need to b e followed by both
SPEP and UPEP for response assessment and categorization;
xExcept for assessment of sCR, CR, and VGPR, patients with â€œmeas urable diseaseâ€ 
restricted to the SPEP will n eed to be followed routinely only by SPEP; 
xPatients with â€œmeasurable diseaseâ€ restricted to the UPEP will need to be followed 
routinely only by UPEP;
xPatients with â€œmeasurable diseas eâ€ in either SPEP or UPEP or bo th will be assessed for 
response only based on t hese two tests and not by the FLC assay ; 
xFLC response criteria are only applicable to patients without m easurable disease in the 
serum or urine, and to fulfill the requirements of the category  of sCR; 
xBone marrow is required only for categorization of CR 
xFor good clinical practice patie nts should be periodically scre ened for light chain escape 
with UPEP or serum FLC assay.
xPlasmacytomas can be staged with CT scans
6.3.2 International Myeloma Working Group uniform response crite ria: 
58
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
6.3.2.1 Stringent Complete Remission (sCR)
xCR as defined below plus
oNormal FLC ratio and
oAbsence of clonal cells in bone m arrow by immunohistochemistry or 
immunofluorescence or flow cytometr y (only1 bone marrow evaluation is needed).
6.3.2.2 Complete Remission (CR) 
xNegative immunofixation on the serum and urine and
xDisappearance of any soft tissue plasmacytomas and
x5% or less plasma cells in bone m arrow (only 1 bone marrow evalu ation is needed)
xNo evidence of progre ssive or new bone lesi ons if radiographic studies were performed
(X-Rays not required in absence of clinical indication)
Comments: To be considered a CR, 
xBoth serum and urine immunofixation m ust be carried out and be negat ive regardless of 
the size of baseline M-protein in the serum or urine; 
xPatients with negative UPEP valu es pretreatment still require U PEP testing to confirm 
CR and exclude light cha in or Benceâ€“Jones escape 
6.3.2.3 Very Good Partial Remission (VGPR) 
xSerum and urine M-protein det ectable by immunofixation but not on electrophoresis or
x90% or greater reduction in serum M-protein plus urine M-protein level <100mg per 24 h
xNo evidence of progre ssive or new bone lesi ons if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)
6.3.2.4 Partial Remission (PR)
x50% or greater reduction of serum M-protein and
x90% or greater reduction in 24-h urinary M-protein (or to less than 200mg per 24 h) and
x50% or greater reduction in the s ize of soft tissue plasmacytom as, if present at baseline
xNo evidence of progre ssive or new bone lesions if radiographic studies were performed 
(X-Rays not required in absence of clinical indication)
Only if the serum and urine M-protein are not measurable (as per  definition in section 
6.2.1.1),
x50% or greater decrease in the  difference between involved and uninvolved FLC levels 
is required (in lieu of the ser um and urine M-protein criteria) .
If serum and urine M-protein are  not measurable and serum FLC a ssay is also not 
measurable,  
59
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xBefore amendment E: 50% or great er reduction in plasma cells is  required in lieu of M-
protein evaluation (pr ovided baseline bone ma rrow plasma cell p ercentage was 30% or 
greater)
xAfter amendment E: bone marrow  plasma cell will not be used for  PR evalution.
6.3.2.5 Stable Disease (SD) 
xNot meeting criteria for CR, VGPR, PR or prog ressive disease 
(Not recommended for use as an indicator of response; stability of disease is best described by 
providing the time t o progression estimates)
Comments:
xAll response categories require  two consecutive assessments mad e at any time before the 
institution of any new therapy; 
xConfirmation with repeat bone marrow biopsy not needed.
xPresence/absence of clonal FHOOVLVEDVHGXSRQWKHÈ› ÈœUDWLR$QDEQRU PDOÈ›ÈœUDWLRE\
immunohistochemistry and/or imm unofluorescence requires a minim um of 100 plasma cells 
IRUDQDO\VLV$QDEQRUPDOUDWL RUHIOHFWLQJSUHVHQFHRIDQDEQR UPDOFORQHLVÈ›ÈœUDWLRQRI
greater than 4:1 or less than 1:2.
6.3.2.6 Progressive Disease (PD)a
Requires one or more  of the following:
xIncreases of greater or equal  to 25% from the lowest post-treatm ent (nadir) value in
oSerum M-component (minimum ab solute increase of 0.5g/dl) or
oUrine  M-component (minimum ab solute increase of 200mg/24h) or
oPercentage of bone marrow plasma  cells (minimum absolute percen tage of 10%)
oSize of bone lesions or sof t tissue plasmacytoma
oOnly in patients without measurab le serum and urine M-protein l evels:  The 
difference between involved and uni nvolved FLC levels.  The abs olute increase must 
be >10 mg/dL.   The FLC ratio must be abnormal.
xDefinite development of new bone lesions or new plasmacytoma
xDevelopment of hypercalcemia sol ely attributable to the disease (corrected serum 
calcium >11.5 mg/dL)
aAll relapse categories require 2 c onsecutive assessments made a t any time before 
classification as relapse or  progression or institution of a ne w therapy.
6.4 TOXICITY CRITERIA
The following adverse event mana gement guidelines are intended to ensure the safety of each 
patient while on the st udy.  The descriptions and grading scale s found in the revised NCI 
60
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Common Terminology Criteria for A dverse Events (CTCAE) version 4.0 will be utilized for AE 
reporting. All appropriate trea tment areas should have access to a copy of the CTCAE version 
4.0. A copy of the CTCAE version 4.0 can be downloaded from the CTEP web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm#ctc_40 ). 
7SAFETY REPORTING REQUIREMENTS/DATA AND SAFETY MONITORING 
PLAN
7.1 DEFINITIONS
7.1.1 Adverse Event
An adverse event is defined as any reaction, side effect, or un toward event that occurs during the 
course of the clinical trial associated with the use of a drug i n humans, whether or not the event 
is considered related to the tr eatment or clinically significan t. For this study, AEs will include 
events reported by the patient , as well as clinically significa nt abnormal findings on physical 
examination or laboratory eval uation. A new illness, symptom, s ign or clinically significant 
laboratory abnormality or worsening of a pre-existing condition  or abnormality is considered an 
AE.  All AEs must be recorded on the  AE case report form unless o therwise noted above in 
Section 6.1.
All AEs, including clinically s ignificant abnormal findings on laboratory evaluations, regardless 
of severity, will be followed un til return to base line or stabi lization of event. Serious adverse 
events that occur more than 30 days  after the last administrati on of investigational 
agent/intervention and have an attr ibution of at least possibly  related to the agent/intervention 
should be recorded and re ported as per sections 7.2,7.3and7.4.
An abnormal laboratory value will  be considered an AE if the la boratory abnormality is 
characterized by any of the following:
xResults in discontinuation from the study
xIs associated with clinical signs or symptoms 
xRequires treatment or any other  therapeutic intervention
xIs associated with death or anothe r serious adverse event, incl uding hospitalization. 
xIs judged by the Investigator to be of significant clinical imp act
xIf any abnormal laboratory resu lt is considered clinically sign ificant, the investigator will 
provide details about the  action taken with r espect to the test  drug and about the patientâ€™s 
outcome.
7.1.2 Suspected adverse reactionSuspected adverse reaction means any adverse event for which th ere is a reasonable possibility 
that the drug caused the advers e event. For the purposes of IND  safety reporting, â€˜reasonable 
possibilityâ€™ means there is evidence to suggest a causal relati onship between the drug and the 
adverse event. A suspected adve rse reaction implies a lesser de gree of certainty about causality 
than adverse reaction, which mean s any adverse event caused by a drug.
7.1.3 Unexpected adverse reaction
61
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
An adverse event or suspected adv erse reaction is considered â€œunexpectedâ€ if it is not listed in 
the investigator brochure or i s not listed at the specificity o r severity that has been observed; or, 
if an investigator brochure is not required or available, is no t consistent with t he risk information 
described in the general investigational plan or elsewhere in the current application. 
"Unexpectedâ€ also refers to adve rse events or suspected adverse  reactions that are mentioned in 
the investigator brochure as occu rring with a class of drugs or as anticipated from the 
pharmacological properties of the drug, but are not specificall y mentioned as occurring with the 
particular drug und er investigation.
7.1.4 Serious 
An Unanticipated Problem or Proto col Deviation is serious if it me ets the definition of a Serious 
Adverse Event or if it compromises  the safety, welfare or rights  of subjects or others.
7.1.5 Serious Adverse EventAn adverse event or suspected adv erse reaction is considered se rious if in the view of the 
investigator or the sponsor, it results in any of the following :
xDeath,
xA life-threatening adverse drug experience
xInpatient hospitalization or prolongation of existing hospitali zation
xPersistent or significant incap acity or substantial disruption of the ability to conduct 
normal life functions
xA congenital anomaly/birth defect.
xImportant medical events that m ay not result in death, be life- threatening, or require 
hospitalization may be considered a  serious adverse drug experi ence when, based upon
appropriate medical judgment, t hey may jeopardize the patient or subject and may require 
medical or surgical interventi on to prevent one of the outcomes listed in this definition.
7.1.6 Disability
A substantial disruption of a pe rsonâ€™s ability to conduct norma l life functions.
7.1.7 Life-threatening adverse drug experienceAny adverse event or suspected adverse reaction that places the patient or subject, in the view of 
the investigator or sponsor, at immediate risk of death from the  reaction as it occurred, i.e., it 
does not include a reac tion that had it occurred in a more seve re form, might have caused death.
7.1.8 Protocol Deviation (NIH Definition)Any change, divergence, or departure from the IRB-approved research protocol.  7.1.9 Non-compliance (NIH Definition)The failure to comply with appli cable NIH Human Research Protec tions Program (HRPP)
policies, IRB require ments, or regulatory requirements for the protection of human research 
subjects.7.1.10 Unanticipated Problem
62
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Any incident, experie nce, or outcome that:
xIs unexpected in terms of nature , severity, or frequency in rel ation to 
(a) the research risks that ar e described in the IRB-approved r esearch protocol and 
informed consent document; Inves tigatorâ€™s Brochure or other stu dy documents, and
(b) the characteristics of t he subject population being studied ; AND
xIs related or possibly related t o participation in the research ; AND
xSuggests that the research places subjects or others at a greater risk of harm (including 
physical, psychological, economic , or social harm) than was prev iously known or 
recognized.
7.2 NCI-IRB AND CLINICAL DIRECTOR REPORTING
7.2.1 NCI-IRB and NCI CD Expedited Reporting of Unanticipated Pro blems and Deaths
The Protocol PI will report in the NIH Problem Form to the NCI-IR B and NCI Clinical Director:
xAll deaths, except deaths  due to progressive disease
xAll Protocol Deviations
xAll Unanticipated Problems
xAll non-compliance
Reports must be received withi n 7 days of PI awareness via iRIS .
7.2.2 NCI-IRB Requirements for PI Reporting at Continuing Review
The protocol PI will report to the NCI-IRB: 
1. A summary of all protocol devia tions in a tabular format to in clude the date the deviation 
occurred, a brief description of  the deviation and any correcti ve action.
2. A summary of any instances of non-compliance
3. A tabular summary of the following adverse events:
xAll Grade 2 unexpected events that are possibly, probabl y or definitely related to the 
research; 
xAll Grade 3 and 4 events that are  possibly, probably or definit ely related to the research; 
xAll Grade 5 events rega rdless of attribution; 
xAll Serious Events rega rdless of attribution. 
NOTE : Grade 1 events are not  required to be reported. 
7.2.3 NCI-IRB Reporting of IND Safety Reports
63
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Only IND Safety Reports that  meet the definition of an unanticipated problem will need to be 
reported to the NCI IRB.
7.3 IND S PONSOR REPORTING CRITERIA
An investigator must immediately report to the sponsor, using th e mandatory MedWatch form 
3500a or equivalent, any serious a dverse event, whether or not cons idered drug related, including 
those listed in the protocol or i nvestigator brochure and must include an assessment of whether 
there is a reasonable possibility that the drug caused the event .
x All Grade 5 (fatal) events (ex cept death due to progressive disease) must be 
reported via email within 24 hours .  A complete report must be submitted within one 
business day. 
x All other serious adverse events including deaths due to progre ssive disease must 
be reported withi n one business day
Study endpoints that are serious adverse events (e.g. all-cause  mortality) must be reported in 
accordance with the protocol unless there is evidence suggestin g a causal relationship between 
the drug and the event (e.g. deat h from anaphylaxis).  In that c ase, the investigator must 
immediately report the death to the sponsor.Events will be submitted to the Center for Cancer Research (CCR ) at: CCRsafety@mail.nih.gov
and to the CCR PI and study coordinator.7.3.1 Reporting Pregnancy
7.3.1.1 Maternal exposure
If a patient becomes pregnant durin g the course of the study, t he study treatment should be 
discontinued immediately and the  pregnancy reported to the Spon sor. The potential risk of 
exposure of the fetus to the inve stigational agent(s) or chemot herapy agents (s) should be 
documented in box B5 of the MedWatc h form â€œDescribe Event or Pr oblemâ€.
Pregnancy itself is not regarde d as an SAE. However, as patients who become pregnant on study 
risk intrauterine exposure of t he fetus to agents which may be teratogenic, the CCR is requesting 
that pregnancy should be reporte d in an expedited manner as Gra de 3 â€œPregnancy, puerperium 
and perinatal conditions - Other (p regnancy)â€ under the Pregnanc y, puerperium and perinatal 
conditions SOC. Congenital abnormalities or birt h defects and spontaneous misca rriages should be reported and 
handled as SAEs. Elective abor tions without complications shoul d not be handled as AEs. The 
outcome of all pregnancies (spontan eous miscarriage, elective t ermination, ectopic pregnancy, 
normal birth, or congenital a bnormality) should be followed up and documented.
If any pregnancy occurs in the c ourse of the study, then the in vestigator should inform the 
Sponsor within 1 day, i.e., imme diately, but no later than 24 h ours of when he or she becomes 
aware of it.The designated Sponsor represent ative will work with the invest igator to ensure that all relevant 
information is provided to the S ponsor within 1 to 5 calendar days for SAEs and within 30 days 
for all other pregnancies.
64
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
The same timelines apply when outcome information is available.
7.3.1.2 Paternal exposure
Male patients should refrain from fathering a child or donating  sperm during the study treatment, 
and for 4 months after fini sh the last cell infusion
Pregnancy of the patientâ€™s part ner is not considered to be an AE. However, the outcome of all 
pregnancies (spontaneous miscarri age, elective termination, ectopic pregnancy, normal birth, or 
congenital abnormality) occurring from the date of the first do se until (120 days) after the last 
dose after last cell infusion s hould, if possible, be followed up  and documented.
7.4 INSTITUTIONAL BIOSAFETY COMMITTEE (IBC) R EPORTING CRITERIA
7.4.1 Serious Adverse Event Reports to IBC
The Principal Investigator (or  delegate) will notify IBC of any u nexpected fatal or life-
threatening experience associated with the use of  anti-BCMA CAR  T cells as soon as possible 
but in no event later than 7 cale ndar days of initial receipt o f the information. Serious adverse  
events that are unexpected and assoc iated with the  use of the an ti-BCMA CAR-expressing T
cells, but are not fatal or  life-threatening, must be reported t o the NIH IBC as soon as possible, 
but not later than 15 calendar days  after the investigatorâ€™sini tial receipt of the information.
Adverse events may be reporte d by using the FDA Form 3500a.
7.4.2 Annual Reports to IBCWithin 60 days after the one-yea r anniversary of the date on wh ich the IBC approved the initial 
protocol, and after each subseque nt anniversary until the trial  is completed, the Principal 
Investigator (or delegate) sha ll submit the information describ ed below. Alternatively, the IRB 
continuing review report can be s ent to IBC in lieu of a separat e report.  Please include the IBC 
protocol number on the report.
7.4.2.1 Clinical Trial Information
A brief summary of the status of  the trial in progress or complet ed during the previous year. The 
summary is required to include t he following information: 
xthe title and purpose of the trial
xclinical site
xthe Principal Investigator
xclinical protocol identifierspa rticipant population (such as di sease indication and general 
age group, e.g., adult or pediatric); 
xthe total number of participan ts planned for i nclusion in the t rial; the number entered into 
the trial to date whose particip ation in the trial  was completed ; and the number who 
dropped out of the trial with a br ief description of the reason s
xthe status of the trial, e.g., open to accrual of subjects, clo sed but data collection ongoing, 
or fully completed, 
xif the trial has been complete d, a brief description of any stu dy results. 
65
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
7.4.2.2 Progress Report and Data Analysis
Information obtained during the previous year's clinical and no n-clinical investigations, 
including: 
xa narrative or tabul ar summary showing the most frequent and mo st serious adverse 
experiences by body system
xa summary of all serious advers e events submitted during the pa st year
xa summary of serious adverse eve nts that were expected or consi dered to have causes not 
associated with the use of the ge ne transfer product such as di sease progression or 
concurrent medications
xif any deaths have occurred, the  number of participants who died during participation in 
the investigation and causes of death
xa brief description of any inf ormation obtained that is pertine nt to an understanding of the 
gene transfer productâ€™s actions , including, for example, inform ation about dose-response, 
information from controlled trials, and information about bioav ailability. 
7.5 DATA AND SAFETY MONITORING PLAN
7.5.1 Principal Investigator/Research Team 
The clinical research team wi ll meet on a regular biweekly basi s when patients are being actively 
treated on the trial to discuss each patient. Decisions about d ose level enrollment and dose 
escalation if applicable will be  made based on the toxicity dat a from prior patients. 
All data will be collected in a timely manner and reviewed by the principal investigator. Adverse 
events will be reported as require d above. Any safety concerns,  new information that might 
affect either the ethical and or  scientific conduct of the tria l, or protocol dev iations will be 
immediately reported to the IRB  using iRIS and to the Sponsor. 
The principal investigator will review adverse event and respon se data on each patient to ensure 
safety and data accuracy. The pr incipal investigator will perso nally conduct or supervise the 
investigation and provide appropr iate delegation of responsibili ties to other members of the 
research staff. 
7.5.2 Sponsor Monitoring Plan
As a sponsor for clinical trials, FDA regulations require the C CR to maintain a monitoring 
program. The CCRâ€™s program allo ws for confirmation of: study da ta, specifically data that could 
affect the interpretation of pr imary study endpoints; adherence  to the protocol, regulations, and 
SOPs; and human subjects protec tion. This is done through indep endent verification of study 
data with source docume ntation focusing on:
xInformed consent process
xEligibility confirmation
xDrug administration and accountability
66
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xAdverse events monitoring
xResponse assessment.
The monitoring program also extends to multi-site research when  the CCR is the coordinating 
center.
This trial will be monitored by personnel employed by an NCI co ntractor. Monitors are qualified 
by training and experience to m onitor the progress of clinical trials. Personnel monitoring this 
study will not be affiliated in a ny way with the trial conduct
7.5.3 Safety Monitoring Committee (SMC)This protocol will require oversig ht from the Safety Monitoring  Committee (SMC).  Initial 
review will occur as soon as possi ble after the annual NCI-IRB continuing review date.   
Subsequently, each protocol will  be reviewed as close to annual ly as the quarterly meeting 
schedule permits or more frequently as may be required by the S MC.   For initial and subsequent 
reviews, protocols will not be r eviewed if there is no accrual within the review period. Written 
outcome letters will be generate d in response to the monitoring activities and submitted to the 
Principal investigator and Clinical Director or Deputy Clinical Director, CCR, NCI.
8STATISTICAL CONSIDERATIONS
The primary endpoint of this trial is to determine the safety o f administering anti-BCMA-CAR-
expressing T cells to patients with relapsed or persistent B-ce ll malignancies.  Secondary 
objectives of this trial are to measure any anti-malignancy eff ect that might occur, to assess the 
feasibility of administering anti-BCMA-CAR-expressing T cells, a nd to measure persistence and 
function of anti-BCMA-CAR -expressing T cells. 
The trial was to be a dose-escalation with 5 dose levels.  The n umber of anti-BCMA-CAR-
expressing T cells transferred f or each cohort was originally to  be as follows: 
Dose level 1 0.3x10
6CAR+ T cells per kg of recipient bodyweight
Dose level 2 1.0x106CAR+ T cells per kg of recipient bodyweight 
Dose level 3 3.0x106CAR+ T cells per kg of recipient bodyweight 
Dose level 4 9.0x106CAR+ T cells per kg of recipient bodyweight
Dose level 5 15.0x106CAR+ T cells per kg of recipient bodyweight
As of amendment E, we have completed accrual to the first 3 dos e levels using the approach 
described in the next 3 paragraphs. Each dose level will include  a minimum of 3 patients.  There 
will be a minimum of 7 days betw een the start of the conditioni ng chemotherapy regimen for 
sequential patients.  Patients will be enrolled sequentially; therefore, enrollment will not proceed 
to a higher dose level until all  patients have been treated in t he prior dose level.  If sufficient cells 
cannot be grown to meet the crite ria for the assigned cohort, t he patient will receive the dose of 
67
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
cells called for by one dose le vel lower than the assigned coho rt. If sufficient cells cannot be 
grown to meet the dose requirement called for one dose level lo wer than the assigned cohort, the 
treatment will be aborted. If a DLT occurs in an additional pati ent entered at a lower dose due to 
cell growth limitations, accrual w ill continue at this level as  described in the dose-escalation 
scheme below.  Accrual will be halted at the higher level until  accrual at the lower level is 
complete as described above.
Should none of the first 3 patient s treated on a dose level exp erience a DLT, accrual can start on 
the next higher dose level after a 14-day delay following treat ment of the third patient.  Should 1 
of 3 patients experience a dose limiting toxicity a particular dose level,  three more patients 
would be treated at that dose level to confirm that no greater than 1/6 patients have a DLT prior 
to proceeding to the next higher level.  If 1/6 patients have a  DLT at a particular dose level, 
accrual can proceed to the next higher dose level. If a level w ith 2 or more DLTs in 3-6 patients 
has been identified, 3 additiona l patients will be accrued at t he next-lowest dose for a total of 6, 
in order to further characterize the safety of the maximum tole rated dose.  The maximum 
tolerated dose is the dose at which a maximum of 1 of 6 patient s has a DLT.  After a maximum 
tolerated dose is defined, additional patients can be treated o n this trial: up to 8 total additional 
recipients can be treated after a MTD is established in order to b etter define safety and toxicity at 
that dose level. If cell growth limitations preclude administrat ion of the maximum tolerated 
dose, the patient will receive as  many cells as possible up to the maximum tolerated dose. 
DLTs that occur in the cohort of patients receiving a repeat treatment will not affect the dose 
escalation of patients receiving an initial treatment. However, excessive DLTs among re-
treatments will resu lt in a discontinuati on of this practice. Specifically, if 2-3 of the first 3 
patients re-treated, 3 or more  of the first 6 r e-treated patien ts, 4 or more out of  the first 9 re-
treated patients, or greater th an 1/3 of the total patients rec eiving a repeat treatment experiences 
a DLT during repeat treatment, then repeat treatments will be di scontinued altogether.
As of Amendment E, we have de cided to not enroll patients on do se level 5.  The plan for the 
future of this protocol is t o further explore dose level 4, 9.0 x106 CAR T cells/kg.  We have 
already treated 4 patie nts on dose level 4 (9x106CAR+ T cells/kg).  One o f 4 low-dose patients 
experienced a DLT on dose level  4.  If 2 more patients can be treated on this dose level without a 
DLT, we will declare dose leve l 4 the maximum tolerated dose and proceed to treat 8 patients on 
an expansion cohort as describ ed on page 35 of the protocol. If 2 more patients cannot be treated 
on Dose Level 4 without a DLT, w e will hold discussions with th e FDA and NCI IRB to ask to 
proceed with a lower dose to be de termined at that time.  Regarding the expansion cohort of 8 
patients, if more than 1 patient on this expansion cohort has a DLT, enrollment on the expansion cohort will stop.  We plan to tr eat a maximum of 10 more patients on this protocol (2 more on 
dose level 4 followed by an e xpansion cohort of 8 patients).  W e have decided to not explore 
dose level 5.  As indicated in section 3.3.4, patients may be re-enrolled on the study as new 
patients to allow re-treatment, and these patient s will be cons idered both times in the total sample 
size for the study. With 18 patie nts enrolled as of January 5, 2 017, and an additional planned 
accrual of up to 10 patients, the t rial will enroll no more tha n 30 patients including up to 2
inevaluable patients.
68
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
The degree of persistence of anti-BCMA-CAR-transduced T cells w ill be evaluated by a 
quantitative measure (flow cytom etry or quantitative PCR) in all patients.  Anti-malignancy 
effects will be measured by clini cal response and categorized a ccording to the International 
Uniform Response Criteria fo r Multiple Myeloma (Section 6.2). The clinical multiple myeloma 
responses will be interpreted cautiously in the context of a pilot study which may be used to 
guide parameters for study in f uture protocols if warranted.
All other evaluations of secondary objectives will be performed using exploratory techniques. 
No formal adjustment for multiple comparisons will be used sinc e the evaluations are being done 
to generate hypotheses.
9COLLABORATIVE AGREEMENTS
9.1 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA)
There is a CRADA for this protocol, with Bluebird Bio , Inc. for t he development of lentiviral 
based chimeric antigen receptors (CAR) vectors that target the B cell maturation antigen 
(BCMA) for the treatment of Multiple Myeloma.
CRADA #2936 has been executed between Bluebird Bio, Inc. and the NC I.
10HUMAN SUBJECTS PROTECTIONS 
10.1 RATIONALE FOR SUBJECT SELECTION
xThe patients to be entered in this protocol have multiple myeloma which is an almost 
always incurable disease; moreover, patients will have progress ive or relapsed myeloma 
despite at least 3 prior therapies.  These patients have limited  life expectancies.  Subjects 
from both genders and all racial/ethnic groups are eligible for  this study if they meet the 
eligibility criteria.  To date, there is no information that su ggests that differences in 
disease response would be expected in one group compared to ano ther.  Efforts will be 
made to extend accrual to a representative population, but in t his preliminary study, a 
balance must be struck between patient safety considerations an d limitations on the 
number of individuals exposed to potentially toxic and/or ineff ective treatments on the 
one hand and the need to explore gender and ethnic aspects of c linical research on the 
other hand.  If differences in outcome that correlate to gender  or to ethnic identity are 
noted, accrual may be expanded or a follow-up study may be writ ten to investigate those 
differences more fully.
xMultiple myeloma (MM) remains an incurable disease despite recen t advances in
therapy.
xOver the last 40 years and throug hout the most recent era of im proved therapy with novel 
agents, the depth of the disease response to therapy (including  T- cells targeting B-cell 
maturation antigen) has remaine d the single most predictive fac tor for event free and 
overall survival in MM
xTherefore, improving the rate and depth of responses remains a high priority for clinical 
research in MM.
69
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
xThis justifies the enrollment of all subjects with MM eligible f or T- cells targeting B-cell 
maturation antigen in this phase I /II study in an attempt to imp rove the clinical outcome 
while feasibility and safety are being evaluated.
xBecause patients on previous trial s  o f  C A R  T  c e l l s  h a v e  e x p e r i e nced hypotension, 
tachycardia, prolonged fevers, ne urological toxicities, and dep ressed myocardial function.  
In many cases these toxicities were severe enough to require in tensive care unit 
admission. We will limit enrollment to patients 70 years of age  or less because based on 
our admittedly limited experience with prior CAR-T cell clinica l trials, younger patients 
tolerate and recover from these toxicities better than elderly patients.
10.2 PARTICIPATION OF CHILDREN
Children will not be enrolled on this study.  Multiple myeloma is extremely uncommon in 
children; moreover, since the efficacy of this experimental procedure is unknown, it does not 
seem reasonable to expose child ren to this risk without further  evidence of benefit.  
10.3 PARTICIPATION OF SUBJECTS UNABLE TO GIVE CONSENT
Adults unable to give consent are excluded from enrolling in th e protocol.  However re-consent 
may be necessary and there is a possibility, though unlikely, t hat subjects could become 
decisionally impaired. For this reason and because there is a p rospect of direct benefit from 
research participation (section 10.4DOOVXEMHFWVÂ•DJHZLOOEHRIIHUHGWKHRSSRUWXQLW\WRILO O
in their wishes for research and care, and assign a substitute decision maker on the â€œNIH 
Advance Directive for Health Care and Medical Research Participationâ€ form so that another person can make decisions about their medical care in the event that they become incapacitated 
or cognitively impaired during the course of the study. Note: The PI or AI will contact the NIH Ability to Consent Assessment Team for evaluation.  For those s ubjects that become 
incapacitated and do not have pre-determined substitute decisio n maker, the procedures 
described in MEC Policy 87-4 for appointing a surrogate decisio n maker for adult subjects who
are (a) decisionally impaired, and (b) who do not have a legal guardian or durable power of 
attorney, will be followed.
10.4 E
VALUATION OF BENEFITS AND RISKS/DISCOMFORTS
The experimental treatment has a chance to provide clinical ben efit though this is unknown.  A 
goal of this study is to imp rove upon the number of patients who may benefit from adoptive cell 
therapy by using genetically-modi fied T-cells.  This specific p rotocol is being performed to 
evaluate a genetically modified T-cell therapy for multiple mye loma, which is a n almost always 
incurable disease.  Only patient s with multiple myeloma who hav e progressive or relapsed 
myeloma despite at least 3 prior  lines of therapy will be enroll ed. The risks of the study fall into 
3 general categories.  First, che motherapy that could cause cyt openias is part of  the protocol.  As 
with any chemotherapy that cau ses neutropenia and thrombocytopenia, this chemotherapy could 
cause toxicities such as infec tions and bleeding. The second ca tegory of toxicity is cytokine-
release type toxicities such a s high fevers, hypotension and ne urological toxicities such as 
delirium, obtundation, myoclonus, s eizures, headache, and trans ient focal neurological toxicities 
including aphasia and focal pare sis.  These cytokine-release-ty pe toxicities have been detected in 
other clinical trials of CAR T  cells during the first 2 weeks af ter anti-BCMA CAR T cells were 
infused.4,95The third main category of tox icity is direct  damage to normal tissues by the CAR T 
70
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
cells.  This could happen because  of unexpected expression of B CMA on normal cells or because 
of unexpected cross-reactivity of  the anti-BCMA CAR with protei ns other than BCMA in vivo.  
Another potential toxicity of an ti-BCMA CAR T cells is hypogammaglobulinemia due to 
depletion of plasma cells and mat ure B cells.  Hypogammaglobuli nemia has been a  complication 
of many patients on clinical trials of anti-BCMA CAR-expressing T  cells.4,32
Hypogammaglobulinemia in these pa tients was routinely treated w ith infusions of intravenous 
immunoglobulins.4
The gammaretroviral vector used i n this trial inserts into the T-cell DNA of patients, so in theory, 
insertional mutagenesis could occur, but insertional mutagenesi s has not occurred in any of the 
hundreds of patients treated with m ature T cells that were gene t i c a l l y  m o d i f i e d  b y  
gammaretroviral vectors.34-36
The success of this clinical tri al cannot be predicted at this time.  Because all patients in this 
protocol have advanced multiple myeloma and limited life expectancies the potential benefit is 
thought to outweigh the potential risks.  It is also anticipate d that this study will provide 
scientific information relev ant to tumor immunotherapy.  
10.5 CONSENT AND ASSENT PROCESS AND DOCUMENTATION
The patient, along with family me mbers or friends, will be prese nted with a deta iled description 
of the protocol treatment.  The  specific requirements, objectives, and potential advantages and 
disadvantages will be presented.  T he Informed Consent document is given to the patient who is 
requested to review it and to as k questions prior to agreeing to participate in the treatment 
portion of this protocol.  The pa tient will be reassured that pa rticipation on trial is entirely 
voluntary and that he/she can withdraw or decide against treatm ent at any time without adverse 
consequences.The permission for additional biopsies for researc h will be obtained from patients 
at the time of the biopsy procedure. The research nurse, Princip al Investigator or his designee is 
responsible for obtaining writte n informed consent from the pat ient.
10.5.1 Telephone re-consent procedure
Reconsent on this study may be  obtained via telephone according to the following procedure: the 
informed consent document will be sent to the subject.  An explanation of the study will be 
provided over the telephone aft er the subject has had the oppor tunity to read the consent form.  
The subject will sign and date the informed consent. A witness to the subjectâ€™s signature will 
sign and date the consent.  
The original informed consent  document will be sent back to the  consenting investigator who 
will sign and date the c onsent form with the  date the consent w as obtained via telephone.  
A fully executed copy will be r eturned via mail for the subjectâ€™s records.  The informed consent 
process will be documented on a pr ogress note by the consenting  investigator and a copy of the 
informed consent document and note will be kept in the subjectâ€™ s research record.
10.5.2 Short form consent process for non-English speaking patie nts
If there is an unexpected enrollme nt of a research participant for whom there is no translated 
extant IRB approved consent docum ent, the principal investigato r and/or those authorized to 
obtain informed consent will use th e Short Form Oral Consent Pr ocess as described in MAS 
71
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Policy M77-2, OHSRP SOP 12, 45 CFR 46.117 (b) (2) and 21 CFR 50.2 7 (b) (2).  The summary 
that will be used is the Englis h version of the extant IRB appr oved consent document. Signed 
copies of both the English versi on of the consent and the trans lated short form will be given to 
the subject or their legally aut horized representative and the signed original w ill be filed in the 
medical record.
Unless the PI is fluent in the pr ospective subjectâ€™s language, an interpreter will be present to 
facilitate the conversa tion. Preferably someone who is independ ent of the subject (i.e., not a 
family member) will assist in pr esenting information and obtaining consent. Whenever possible, 
interpreters will be pr ovided copies of the relevant consent do cuments well before the consent 
conversation with the subj ect (24 to 48 hours if possible). 
We request prospective IRB appr oval of the use of the short for m process and will notify the IRB 
at the time of continuing review of the frequency of the use of the Short Form.
11PHARMACEUTICAL INFORMATION  
11.1 RETROVIRAL VECTOR CONTAINING THE ANTI -BCMA CAR G ENE 
The retroviral vector supernatant (PG13-MSGV-11D5-3CD828Z B1) e ncoding a chimeric 
antigen receptor (CAR) directed against B-cell maturation antig en (BCMA) was prepared and 
preserved following cGMP conditions in the Surgery Branch Vecto r Production Facility 
(SBVPF). The retroviral vector utilizes the MSGV retroviral vec tor backbone and consists of 
7007 bps including the 5' LTR from the murine stem cell virus ( promoter), packaging signal 
including the splicing donor (SD) and splicing acceptor sites,  t h e  a n t i - B C M A   C A R  p r o t e i n  
containing a signal peptide from human CD8-alpha, 11D5-3 light chain variable region (11D5-3
VL), linker peptide, 11D5-3 heavy chain variable region (11D5-3  VH), CD8 (hinge and 
transmembrane), CD28 (cytoplasmic region), and TCR zeta (cytopl asmic region), followed by 
the murine stem cell virus 3'LTR. The physical titer was determ ined by RNA dot blot according 
to sponsor certificate. The supernatant will be store d at â€“80 C or shipped on dry ice and stored in the Dept. of 
Transfusion Medicine, NIH or at Cryonix, Rockville, MD. Both st orage facilities are equipped 
with around-the-clock temperatu re monitoring. Upon request, supernatant will be delivered on 
dry ice to be used in in vitro transductions of T cells. There will be no re-use of the same u nit of 
supernatant for different patients. Retroviral titer has been s hown to be stable after immediate 
thawing and immediate use. Hand ling of the vector should follow  the guidelines of Biosafety 
Level-2 (BSL-2). The specific guidelines for Biosafety Level-2 (BSL-2) can be viewed at
http://bmbl.od.nih.gov/sect3bsl2.htm
11.2 CYCLOPHOSPHAMIDE
11.2.1 SourceCyclophosphamide will be purchased by the NIH Clinical Center P harmacy Department from 
commercial sources and is supp lied as a lyophilized powder in v arious vial sizes.
11.2.2 Toxicities
72
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
1) Nausea and vomiting - variable; symptomatically improved with standard anti-emetics 
and/or benzodiazepines [e.g., lorazepam].
2) Water retention â€“ cyclophosphamid e may rarely provoke the synd rome of inappropriate 
antidiuretic hormone secretion a nd resultant hyponatremia, usually manifested 12-48 hours 
after IV administration, necessitating frequent accurate assess ment [q 1-2 hours] of intake, 
urine output and urine specific gr avity. This effect can be cou nteracted by furosemide. 
Fluid restriction is not feasible during administration of high dose cyclophosphamide.
3) Cardiomyopathy - cyclophosphamid e may cause severe, sometimes lethal, hemorrhagic 
myocardial necrosis or congestive cardiomyopathy. Patients may present with congestive 
cardiomyopathy as late as 2 weeks after the last dose of cyclop hosphamide. The clinical 
syndrome has been observed in patients receiving the dose of cy clophosphamide used in 
this protocol. In an attempt to minimize this complication, pat ients with significant cardiac 
dysfunction are excluded from this protocol [see patient eligibi lity]. Congestive failure is 
managed according to standard medical therapeutics.
4) Hemorrhagic cystitis â€“ this is a serious, potentially life-thr eatening complication related to 
injury of the bladder epitheliu m by cyclophosphamide metabolite s.
5) Although sub-clinical hematur ia is not uncommon at this dose level, clinically significant 
hematuria or serious hemorrhage can usually be avoided by maint aining a high urine 
volume and frequent voidings and the administration of Mesna. D iuresis is maintained for 
24 hours after completion of last dose by parenteral infusions of normal saline with 
potassium chloride. Careful monitoring of serum and urine elect rolytes is mandated. 
Furosemide may be required to ensure this diuresis. Continuous bladder irrigation may be 
used for control of significant hematuria.
6) Sterility
7) Less common but serious compli cations include pulmonary fibro sis and secondary 
malignancies. Less common but rev ersible toxicities include alo pecia and skin rash.
11.2.3 Formulation and preparation 
Reconstituted with sterile water for injection to yield a final  concentration of 20 mg/ml as 
described in the package insert.11.2.4 Stability and StorageVials are stored at room temperature. Following reconstitution as directed with sterile water for 
injection, cyclophosphamide is s table for 24 hours at room temp erature or 6 days when kept at 2-
8Â°C.  Once diluted for administration, cyclophosphamide will be  provided an expiration date 
based on the standards set by the  NIH CC Pharmacy Department.
11.2.5 Administration proceduresThe cyclophosphamide used in this regimen will be given as Intr avenous infusion over 30
minutes. 11.3 FLUDARABINE
11.3.1 Source Fludarabine monophosphate will be purchased by the NIH Clinical  Center Pharmacy Department 
from commercial sources and is supplied as a white, lyophilized  powder. Each vial contains 50 
73
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
mg of fludarabine phosphate, 50 mg of mannitol, and sodium hydr oxide to adjust pH.  
Fludarabine is stored a t room temperature.
11.3.2 Toxicity 
Fludarabine toxicities include m yelosuppression (dose limiting toxicity), fever, nausea, vomiting, 
stomatitis, diarrhea, gastrointestinal bleeding, anorexia, edem a, skin rashes, myalgia, headache, 
agitation, hearing loss, transient episodes of somnolence and f atigue, auto-immune hemolytic 
anemia, auto-immune thrombocytope nia, paresthesias, peripheral neuropathy, renal, and 
pulmonary toxicity (interstitial pneumonitis). Severe fatal CNS  toxicity presenting with loss of 
vision and progressive deteriora tion of mental status were enco untered almost exclusively after 
very high doses of fludarabine monophosphate. Such toxicity has  only rarely been demonstrated 
at the 25-30 mg/m2/day dosage of f ludarabine. Very rarely descr ibed complications include 
transfusion-associated graft-ver sus-host disease, thrombotic th rombocytopenic purpura, and liver 
failure. Tumor lysis syndrome following fludarabine administration has been observed, 
especially in patients with advanced bulky disease. Opportunist ic infections (protozoan, viral, 
fungal, and bacterial) have been observed post-fludarabine, esp ecially in heavily pre-treated 
individuals, and in individuals rec eiving fludarabine combined with other agent.
11.3.3 Formulation and preparation 
FLUDARA IV should be prepared for parenteral use by aseptically  adding Sterile Water for 
Injection, USP. When reconstitute d with 2 ml of Sterile Water f or Injection, each ml of the 
resulting solution will contain 25 mg of Fludarabine Phosphate,  25 mg of mannitol, and sodium 
hydroxide to adjust the pH to 7â€“8.5. Fludarabine will be dilute d in 100 to 125ml of either 5% 
dextrose in water or 0.9% sodium c hloride, and infused IV over 30 minutes.
11.3.4 Stability and Storage 
Reconstituted FLUDARA IV should be s tored in the refrigerator b etween 36 and 46 degrees F. 
Because reconstituted FLUDARA IV contains no antimicrobial pres ervative, care must be taken 
to assure the sterility of the prepared solution. Once diluted f or administration, f ludarbine will be 
provided an expirati on date based on the standards set by the N IH CC Pharmacy 
DepartmentAdministration proceduresParenteral drug products should be inspected visually for parti culate matter a nd discoloration 
prior to administration. Fludara bine is administered as an IV in fusion in 100 ml 0.9% sodium 
chloride, USP over 15 to 30 minutes.  Dose reduction for renal impairment
For Creatinine Clearance of 30- 70 mL/min/1.73m2 there will be a 20% dose reduction. If the 
Creatinine Clearance is less th an 30mL/min/1.73m2, Fludarabine will not be administered.  
74
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
12 REFERENCES
1. Gahrton G, Iacobelli S, BjÃ¶rkstrand B, et al. Autologous/reduce d-intensity allogeneic 
stem cell transplantation vs a utologous transplantation in mult iple myeloma: long-term 
results of the EBMT-NMAM2000 study. Blood. 2013;121(25):5055-5063.
2. Salama M, Nevill T, Marcellus D , et al. Donor leukocyte infusion s for multiple myeloma. 
Bone Marrow Transplantation. 2000;26(11):1179-1184.
3. Kalos M, Levine BL, Porter DL, e t al. T cells with chimeric ant igen receptors have potent 
antitumor effects and can establish memory in patients with adv anced leukemia. Science 
Translational Medicine. 2011;3(95).
4. Kochenderfer JN, Dudley ME, Feldm an SA, et al. B-cell depletion and remissions of 
malignancy along with cytokine-a ssociated toxicity in a clinica l trial of anti-CD19 
chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
5. Carpenter RO, Evbuomwan MO, Pittalu ga S, et al. B-cell maturati on antigen is a 
promising target for adoptive T-cell therapy of multiple myelom a. Clinical Cancer 
Research. 2013;19(8):2048-2060.
6. Gattinoni L, Finkelstein SE, Kle banoff CA, et al. Removal of hom eostatic cytokine sinks 
by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ 
T cells. Journal of Experimental Medicine. Oct 3 2005;202(7):907-912.
7. Kochenderfer JN, Yu Z, Frasheri D, Restifo NP, Rosenberg SA. Ad optive transfer of 
syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymp homa and normal B cells. Blood. 2010;116(19):3875-3886.
8. North RJ. Cyclophosphamide-fac ilitated adoptive immunotherapy o f an established 
tumor depends on elimina tion of tumor-induced suppressor T cell s. Journal of 
Experimental Medicine. 1982;155(4):1063-1074.
9. Palumbo A, Anderson K. Multiple myeloma. New England Journal of Medicine. 
2011;364(11):1046-1060.
10. Munshi NC, Anderson KC. Plasma Ce ll Neoplasms. In: DeVita VT, L awrence TS, 
Rosenberg SA, eds. Cancer:  Principles and Practice of Oncology 9th ed 2011.
11. Messina C, Locatelli F, Lanino E , et al. Extracorporeal photoch emotherapy for paediatric 
patients with graft-versus-host  disease after haematopoietic st em cell transplantation. Br J 
Haematol. Jul 2003;122(1):118-127.
12. Rajkumar SV. Treatment of multiple myeloma. Nature Reviews Clinical Oncology. 
2011;8(8):479-491.
13. Cherr
y BM, Korde N, Kwok M, Roschewski M, Landgren O. Evolving therapeutic 
paradigms for multiple myeloma: Back to the future. Leukemia and Lymphoma. 
2013;54(3):451-463.
14. Gonsalves WI, Gertz MA, Lacy MQ,  et al. Second auto-SCT for tre atment of relapsed 
multiple myeloma. Bone Marrow Transplantation. 2013;48(4):568-573.
75
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
15. Durie BGM, Harousseau JL, Miguel JS, et al. International unifo rm response criteria for 
multiple myeloma. Leukemia. 2006;20(9):1467-1473.
16. Jakubowiak A. Management Strategies  for Relapsed/Refractory Mul tiple Myeloma: 
Current Clinical Perspectives. Seminars in Hematology. 2012;49(SUPPL. 1):S16-S32.
17. Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple 
myeloma relapsing after therapy with IMiDs and bortezomib: A mu lticenter international 
myeloma working group study. Leukemia. 2012;26(1):149-157.
18. Stadtmauer EA, Weber DM, Niesviz ky R, et al. Lenalidomide in co mbination with 
dexamethasone at first relapse in comparison with its use as la ter salvage therapy in 
relapsed or refractory multiple myeloma. European Journal of Haematology. 
2009;82(6):426-432.
19. Bensinger WI. The current status  of reduced-intensity allogenei c hematopoietic stem cell 
transplantation for  multiple myeloma. [Review] [48 refs]. Leukemia. 2006;20(10):1683-
1689.
20. Zeiser R, Finke J. Allogeneic haem atopoietic cell transplantati on for multiple myeloma: 
reducing transplant-related mortality while harnessing the graf t-versus-myeloma effect. 
[Review] [70 refs]. European Journal of Cancer. 2006;42(11):1601-1611.
21. Bruno B, Rotta M, Patriarca F, e t al. A comparison of allograft ing with autografting for 
newly diagnosed myeloma. New England Journal of Medicine. 2007;356(11):1110-1120.
22. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Current Opinion in 
Immunology. 2010;22(2):251-257.
23. Park TS, Rosenberg SA, Morgan RA . Treating cancer with genetica lly engineered T 
cells. Trends in Biotechnology. 2011;29(11):550-557.
24. Morgan RA, Dudley ME, Wunderlic h JR, et al. Cancer regression i n patients after 
transfer of genetically engineered lymphocytes.[see comment]. Science. Oct 6 
2006;314(5796):126-129.
25. Rosenberg SA. Cell transfer imm unotherapy for metastatic solid cancer-what clinicians 
need to know. Nature Reviews Clinical Oncology. 2011;8(10):577-585.
26. Restifo NP, Dudley ME, Rosenbe rg SA. Adoptive immunotherapy for  cancer: 
Harnessing the T cell response. Nature Reviews Immunology. 2012;12(4):269-281.
27. Kershaw MH, Teng MWL, Smyth MJ, Darcy PK. Supernatural T cells:  Genetic 
modification of T cells for cancer therapy. Nature Reviews Immunology. 2005;5(12):928-940.
28. Hoyos V, Savoldo B, Dotti G. G enetic modification of human T ly mphocytes for the 
tr 
eatment of hematologic malignancies. Haematologica. 2012;97(11):1622-1631.
29. Turtle CJ, Hudecek M, Jensen MC, R iddell SR. Engineered T cells for anti-cancer 
therapy. Current Opinion in Immunology. 2012;24(5):633-639.
76
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
30. Brentjens RJ, RiviÃ¨re I, Park JH , et al. Safety and persistence  of adoptively transferred 
autologous CD19-targeted T cells in patients with relapsed or ch emotherapy refractory B-
cell leukemias. Blood. 2011;118(18):4817-4828.
31. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with 
metastatic synovial cell sarcom a and melanoma using genetically  engineered
lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology. 2011;29(7):917-
924.
32. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient  treated with autologous T c ells genetically 
engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
33. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and 
persistence of chimeric antigen receptor-modified T cells in ly mphoma patients. Journal 
of Clinical Investigation. 2011;121(5):1822-1826.
34. Scholler J, Brady TL, Binder-Sc holl G, et al. Decade-long safety and function of 
retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine. 
2012;4(132).
35. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integr ation deregulates gene 
expression but has no consequen ce on the biology and function o f transplanted T cells. 
Proceedings of the National Academy of Sciences of the United States of America. 2006;103(5):1457-1462.
36. Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV- specific T-cell 
infusions to prevent or treat EBV -related lymphoproliferative d isease in transplant 
recipients. Blood. 2010;115(5):925-935.
37. Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric anti gen receptor with 
modified signaling domains leads to enhanced survival of transd uced T lymphocytes and 
antitumor activity. Journal of Immunology. 2009;183(9):5563-5574.
38. Irving BA, Weiss A. The cytoplasmic domain of the T cell recept or zeta chain is 
sufficient to couple to receptor-associated signal transduction pathways. Cell. Mar 8 
1991;64(5):891-901.
39. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation an d targeting of cytotoxic 
lymphocytes through chimeric sing le chains consisting of antibo dy-binding domains and 
the gamma or zeta subunits of the  immunoglobulin and T-cell rec eptors. Proceedings of 
the National Academy of Sciences of the United States of America. Jan 15 
1993;90(2):720-724.
40. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long -term fate of chimeric 
antig
en receptor-positive T cells  in patients with neuroblastom a. Blood. 
2011;118(23):6050-6056.
41. Curran KJ, Pegram HJ, Brentjens R J. Chimeric antigen receptors for T cell 
immunotherapy: Current understa nding and future directions. Journal of Gene Medicine. 
2012;14(6):405-415.
77
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
42. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells eng ineered to coexpress 
tumor-specific receptors: persistence and antitumor activity in  individuals with 
neuroblastoma.[see comment]. Nature Medicine. Nov 2008;14(11):1264-1270.
43. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer ce lls by human 
lymphocytes redirected with a c himeric gene composed of an anti body variable region 
and the Fc receptor gamma chain. Journal of Experimental Medicine. Jul 1 
1993;178(1):361-366.
44. Hwu P, Yang JC, Cowherd R, et al . In vivo antitumor activity of  T cells redirected with 
chimeric antibody/T-cell receptor genes. Cancer Research. Aug 1 1995;55(15):3369-
3373.
45. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive 
immunotherapy using gene-modified T  cells for ovarian cancer. Clinical Cancer 
Research. Oct 15 2006;12(20 Pt 1):6106-6115.
46. Kochenderfer JN, Feldman SA , Zhao Y, et al. Construction and pr eclinical evaluation of
an anti-CD19 chimeric antigen receptor. Journal of Immunotherapy. 2009;32(7):689-702.
47. Cheadle EJ, Gilham DE, Thistleth waite FC, Radford JA, Hawkins R E. Killing of non-
Hodgkin lymphoma cells by autologous CD19 engineered T cells. British Journal of 
Haematology. May
May 2005;129(3):322-332.
48. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of syst emic B-cell tumors by 
genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-
15.[see comment]. Nature Medicine. Mar 2003;9(3):279-286.
49. Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling 
capacity provoke potent cytotoxicity against acute lymphoblasti c leukemia. Leukemia. 
Apr 2004;18(4):676-684.
50. Milone MC, Fish JD, Carpenito C , et al. Chimeric receptors cont aining CD137 signal 
transduction domains mediate enha nced survival of T cells and increased antileukemic 
efficacy in vivo. Molecular Therapy: the Journal of  the American Society of Gene 
Therapy. Aug 2009;17(8):1453-1464.
51. Porter DL, BL; Kalos, M et al. Chimeric Antigen Receptor-Modifi ed T Cells in Chronic 
Lymphoid Leukemia. The New England Journal of Medicine. 2011;365(8):725-733.
52. Wang X, Naranjo A, Brown CE, e t al. Phenotypic and functional a ttributes of lentivirus-
modified CD19-specific H uman CD8 + central memory T cells manufa ctured at clinical 
scale. Journal of Immunotherapy. 2012;35(9):689-701.
53. Cooper LJ, Topp MS, Serrano LM, e t al. T-cell clones can be rendered specific for 
CD19: toward the selective augmen tation of the graft-versus-B-l ineage leukemia effect. 
Blood. F
eb 15 2003;101(4):1637-1644.
54. Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cel ls to augment disease 
control in patients undergoing a utologous hemato poietic stem-ce ll transplantation for 
advanced B-lymphoid malignancies. Human Gene Therapy. 2012;23(5):444-450.
78
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
55. Hollyman D, Stefanski J, Przyby lowski M, et al. Manufacturing v alidation of biologically 
functional T cells targeted to CD19 antigen for autologous adop tive cell therapy. Journal 
of Immunotherapy. 2009;32(2):169-180.
56. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor l ocalization, and antitumor 
activity of CAR-engineered T cells is enhanced by costimulatory  signaling through 
CD137 (4-1BB). Cancer Research. 2011;71(13):4617-4627.
57. Maher J, Brentjens RJ, Gunset G, RiviÃ¨re I, Sadelain M. Human T-lymphocyte 
F\WRWR[LFLW\DQGSUROLIHUDWLRQGLU HFWHGE\DVLQJOHFKLPHULF7& 5È—&'UHFHSWRUNature 
Biotechnology. 2002;20(1):70-75.
58. Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric imm une receptors: Evaluation of four  different scFvs and 
antigens. Journal of Immunotherapy. 2005;28(3):203-211.
59. Rossig C, Bar A, Pscherer S, et al. Target antigen expression o n a professional antigen-
presenting cell induces superior proliferative antitumor T-cell  responses via chimeric T-
cell receptors. Journal of Immunotherapy. Jan-Feb 2006;29(1):21-31.
60. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen imp acts the long-term engraftmen t but not antitumor 
activity of CD19-specific engineered T cells. Journal of Immunology. 2010;184(4):1885-
1896.
61. Brentjens RJ, Santos E, Nikhamin Y, et al. Genetically targeted T cells eradicate systemic 
acute lymphoblastic leukemia xenografts. Clinical Cancer Research. Sep 15 2007;13(18 
Pt 1):5426-5435.
62. Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation prov ided through a 
CD19-specific chimeric antigen r eceptor enhances in vivo persis tence and antitumor 
efficacy of adoptively transferred T cells. Cancer Research. Nov 15 2006;66(22):10995-
11004.
63. Porter CD, Collins MK, Tailor CS, et al. Compa rison of efficien cy of infection of human 
gene therapy target cells via f our different retroviral recepto rs. Human Gene Therapy. 
May 20 1996;7(8):913-919.
64. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene reject ion responses contribute 
to attenuated persisten ce of adoptively transferred CD20/CD19-s pecific chimeric antigen 
receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation. 
2010;16(9):1245-1256.
65. Laabi Y, Gras MP, Carbonnel F , et al. A new gene, BCM, on chrom osome 16 is fused to 
the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a  malignant T cell 
l
ymphoma. EMBO Journal. 1992;11(11):3897-3904.
66. Laabi Y, Gras MP, Brouet JC, Berger R, Larsen CJ, Tsapis A. The  BCMA gene, 
preferentially expressed during B lymphoid maturation, is bidir ectionally transcribed. 
Nucleic Acids Research. 1994;22(7):1147-1154.
79
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
67. Novak AJ, Darce JR, Arendt BK, e t al. Expression of BCMA, TACI,  and BAFF-R in 
multiple myeloma: A mechanism for growth and survival. Blood. 2004;103(2):689-694.
68. Neri P, Kumar S, Fulciniti MT, e t al. Neutralizing B-cell-activ ating factor antibody 
improves survival and inhibits oste oclastogenesis in a severe c ombined immunodeficient 
human multiple myeloma model. Clinical Cancer Research. 2007;13(19):5903-5909.
69. Bellucci R, Alyea EP, Chiaretti S , et al. Graft-versus-tumor re sponse in patients with 
multiple myeloma is associated with antibody response to BCMA, a plasma-cell 
membrane receptor. Blood. 2005;105(10):3945-3950.
70. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect  myeloma cells from 
apoptosis induced by interleuki n 6 deprivation and dexamethasone . Blood. 
2004;103(8):3148-3157.
71. Thompson JS, Schneider P, Kalle d SL, et al. BAFF binds to the t umor necrosis factor 
receptor-like molecule B cell maturation antigen and is importa nt for maintaining the 
peripheral B cell population. Journal of Experimental Medicine. 2000;192(1):129-135.
72. Mackay F, Schneider P, Rennert P , Browning J. BAFF and APRIL: A  tutorial on B cell 
survival .Vol 21. Annual Review of Immunology2003:231-264.
73. Kalled SL. The role of BAFF i n immune function and implications for autoimmunity. 
Immunological Reviews. 2005;204:43-54.
74. Tai YT, Li XF, Breitkreutz I, et al. Role of B-cell-activating factor in adhesion and 
growth of human multiple myeloma  cells in the bone marrow micro environment. Cancer 
Research. 2006;66(13):6675-6682.
75. O'Connor BP, Raman VS, Erickson LD, et al. BCMA Is Essential fo r the Survival of 
Long-lived Bone Marrow Plasma Cells. Journal of Experimental Medicine. 
2004;199(1):91-97.
76. Ng LG, Sutherland APR, Newton R, e t al. B cell-activating facto r belonging to the TNF 
family (BAFF)-R is the principal BAFF receptor facilitating BAF F costimulation of 
circulating T and B cells. Journal of Immunology. 2004;173(2):807-817.
77. Xu S, Lam KP. B-cell maturation pr otein, which binds the tumor necrosis factor family 
members BAFF and APRIL, is dispen sable for humoral immune respo nses. Molecular 
and Cellular Biology. 2001;21(12):4067-4074.
78. Schiemann B, Gommerman JL, Vora K, et al. An esse ntial role for  BAFF in the normal 
development of B cells through a BCMA-independent pathway. Science. 
2001;293(5537):2111-2114.
79. B randtzaeg P. Function of mucosa-associated lymphoid tissue in antibody formation. 
Immunological Investigations. 2010;39(4-5):303-355.
80. Soutar CA. Distribution of plas ma cells and other cells contain ing immunoglobulin in the 
respiratory tract of normal ma n and class of immunoglobulin con tained therein. Thorax. 
1976;31(2):158-166.
80
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
81. Kalled SL, Hsu Y. Anti-BCMA Antibodies. World Intellectual Property Organization 
Patent. Filing date 10 March 2010;Interna tional Publicaton Number WO 20 10/104949 
A2(Patent Applicant Biogen  Idec, Cambridge MA, USA).
82. Rubio V, Stuge TB, Singh N, et al . Ex vivo identification, isolation and analysis of 
tumor-cytolytic T cells. Nature Medicine. 2003;9(11):1377-1382.
83. Muranski P, Boni A, Wrzesinski C , et al. Increased intensity ly mphodepletion and 
adoptive immunotherapy - How far can we go? Nature Clinical Practice Oncology. 
2006;3(12):668-681.
84. Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP. Sinks, suppressors and 
antigen presenters: How lymphodepletion enhances T cell-mediate d tumor 
immunotherapy. Trends in Immunology. 2005;26(2):111-117.
85. Dumitru CA, Moses K, Trellakis S,  Lang S, Brandau S. Neutrophil s and granulocytic 
myeloid-derived suppressor cells: Immunophenotyping, cell biolo gy and clinical 
relevance in human oncology. Cancer Immunology, Immunotherapy. 2012;61(8):1155-
1167.
86. Lee JC, Hayman E, Pegram HJ, et al. In vivo inhibition of human  CD19-targeted effector 
T cells by natural T regulatory cells in a xenotransplant murine model of B cell 
malignancy. Cancer Research. 2011;71(8):2871-2881.
87. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in 
patients after clonal repopula tion with antitumor lymphocytes. Science. Oct 25 
2002;298(5594):850-854.
88. Dudley ME, Yang JC, Sherry R, e t al. Adoptive cell therapy for patients with metastatic 
melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. 
Journal of Clinical Oncology. Nov 10 2008;26(32):5233-5239.
89. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the flud arabine and 
cyclophosphamide combination regimen in chronic lymphocytic leu kemia. Journal of 
Clinical Oncology. 2001;19(5):1414-1420.
90. Klebanoff CA, Gattinoni L, Palme r DC, et al. Determinants of su ccessful CD8 + T-cell 
adoptive immunotherapy for large  established tumors in mice. Clinical Cancer Research. 
2011;17(16):5343-5352.
91. Overwijk WW, Theoret MR, Finkels tein SE, et al. Tumor regressio n and autoimmunity 
after reversal of a functionally tolerant state of self-reactiv e CD8+ T cells. Journal of 
Experimental Medicine. 2003;198(4):569-580.
92. Li S, Yang J, Urban FA, et al. Genetically engineered T cells e xpressing a HER2-specific 
chimeric receptor mediate antigen-spe cific tumor regression. Cancer Gene Therapy. 
2008;15(6):382-392.
93. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological 
malignancies after stem cell transplantation revisited. Cancer Treatment Reviews. 
2010;36(7):528-538.
81
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
94. Tomblyn M, Lazarus HM. Donor lymphocyte infusions: The long and  winding road: how 
should it be traveled? Bone Marrow Transplantation. 2008;42(9):569-579.
95. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cell s rapidly induce molecular 
remissions in adults with chemotherapy-refractory acute lymphob lastic leukemia. Science 
Translational Medicine. 2013;5(177).
96. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T ce lls expressing anti-
CD19 chimeric antigen receptors. Nature Reviews Clinical Oncology. 2013;10(5):267-
276.
 
82
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
 
13APPENDICES
13.1 APPENDIX A-P ERFORMANCE STATUS CRITERIA
ECOG Performance Status Scale*
Grade Descriptions
0Normal activity.  Fully active , able to carry on all pre-diseas e 
performance without restriction.
1Symptoms, but ambulatory.  Restricted in physically strenuous a ctivity, 
but ambulatory and able to car ry out work of a light or sedenta ry nature 
(e.g., light housework, office work).
2In bed <50% of the time.  Ambulat ory and capable of all self-ca re, but 
unable to carry out any work activities.  Up and about more tha n 50% 
of waking hours.
3In bed >50% of the time.  Cap able of only limited self-care, co nfined to 
bed or chair more tha n 50% of waking hours.
4100% bedridden.  Completely disa bled.  Cannot carry on any self -care.  
Totally confined to bed or chair.
5 Dead.
* As published in Am. J. Clin. Oncol.: Oken, M.M., Creech, R.H. , Tormey, D.C., Horton, J., 
Davis, T.E., McFadden, E.T., Car bone, P.P.: Toxicity And Respon s e  C r i t e r i a  O f  T h e  E a s t e r n  
Cooperative Oncology Gr oup. Am J Clin Oncol 5:649-655, 1982.
83
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.2 APPENDIX B: D ATA COLLECTION ELEMENTS REQUIRED BYPROTOCOL 
All of the following elements will be recorded i n the C3D datab ase:
A. Patient Enrollment
xDate of birth, age, gender, race, ethnicity
xHeight
xWeight
xPerformance Status
xDate of original diagnosis
xStage at diagnosis
xPlasmacytoma present: Yes or No
xTumor Histology and date of confirmation
xBCMA expression by tumor type of tissue studied and date of conf irmation
xDate of Informed Consent signat ure, consent version and date of  registration
xBaseline History/Physical
xBaseline Symptoms 
xPrior therapy
xPrior radiation
xPrior Bone Marrow Biopsy that inc ludes the percent of plasma ce lls and the percent 
of BCMA cells
xFindings of consultations done at screening
B. Study Drug administration and re sponse for eac h course of the rapy given
xDates anti-BCMA-CAR-transduced T cells given
xDose level, actual dose, s chedule and route given
xHeight, weight, and body surface  area at start of each course
xResponse assessment for each restaging performed
xConcomitant medications will not be collected in C3D
C. Laboratory and Diagnostic Test Data
1. All Clinical laboratory and diagnostic test results done at s creening and until day 
30 post infusion with the following exceptions:
Diagnostic tests which are not specified in the protocol, and i f the results are not 
needed to document the start or  end of an adverse event that re quires reporting.
Serologies-CMV, HSV, EBV, toxoplas mosis, adenovirus (patient and donor)
TTV data 
2. All staging studies including  serum protein electrophoresis, urine protein 
electrophoresis, serum free light chains, bone marrow biopsy reports, flow cytometry reports, serum immunoglobulin reports including beta-2  microglobulin,
84
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
complete blood count and differential reports, serum creatinine  reports, TBNK 
results, serum protein, urine albumin, serum calcium (including i onized), ESR and 
CRP results. MRI, X-ray (including skeletal survey), and CT scan  r e s u l t s  w i l l  
only be reported if they were used for staging.
D. Adverse Events
Please see section 6.1.1 Adverse Event Recording
E. Tumor response and measurements
xRestaging studies performed at protocol specified time points a nd as clinically 
indicated.
xAny physical exam findings will be  collected as Adverse Events an d labs results.
xYears 5-15 follow-up is only for survival.
F. Off study
xDate and reason for off study
xDate and cause of death
xAutopsy findings
xPI decision to end this study
85
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.3 APPENDIX C: G UIDELINES FOR MANAGEMENT OF COMMON TOXICITIES THAT OCCUR 
AFTER CAR T- CELL INFUSIONS
Infusions of CAR T cells are often complicated by significant ac ute toxicities in the first 2 to 3 
weeks after the infusion.  In many cases the toxicities correla te with serum inflammatory 
cytokine levels.4
The toxicities most often experienced by patients receiving inf usions of anti-BCMA CAR T cells 
include, but are not limited to, tumor lysis syndrome, fever, f atigue, hypotension, tachycardia, 
acute renal failure, and neurological toxicities such as aphasi a, ataxia, headache, somnolence, 
and coma.  Fever is usually the first toxicity to occur.  CARs targeting different antigens than 
BCMA might have different toxicities.
Suggested Guidelines for comm on acute CAR T-cell toxicities
Note these are guidelines that mig ht require modification based  on clinical circumstances of each 
patient, and failure to e xactly follow these guidelines is not a protocol deviation.
Administration of cor ticosteroids should be  avoided if at all p ossible to avoid killing or 
impairing the function of the CAR T cells.
1. All patients with significant  malignancy burdens and without a contradiction such as allergy 
should be started on allopurinol at the time of the start of the  chemotherapy conditioning 
regimen or 1 day before the CAR T cell infusion. The suggested a llopurinol dose is 200 to 
300 mg/day with a possible loading dose of 300 to 400 mg. 
2. Vital signs should be checked  a minimum of every 4 hours duri ng hospitalization.  
Increasing the time interval between vital sign checks for patien t convenience or other 
reasons should be avoided.
3. Strict ins and outs should  be recorded on all patients.
4. Fevers should be treated with acetaminophen and comfort measu res. NSAIDs and 
corticosteroids should be avoided.
5. Administer fresh frozen plasma (FFP) for a PTT 1.5-fold or mo re above the upper limit of 
normal.
6. For patients with an increased PTT, check the fibrinogen leve l and keep the fibrinogen level 
above 100 mg/dL with cryoprecipitate.
7. Patients with a heart rate persistently higher than 115/minute  and fever should have vital 
signs checked every 2 hours.
8. Patients who are neutropenic and febrile should be receiving broad-spectrum antibiotics.
9. Patients at risk of syncope   
Patients on this protocol will  be placed on strict fall precaut ions including instructions to get out 
of bed only with assistance under the following conditions:
86
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
1. Any history of syncope or near-syncope within 1 month before Anti BCMA CAR T-cell 
infusion or any time after CAR T-cell infusion.
2. Any blood pressure reading of l ess than 90 mm Hg systolic blood pressure after anti-
BCMA CAR T-cell infusion.
3. Heart rate greater than 100 beats per minute.
Any patient with syncope, near-syncope, or light-headedness wil l have orthosta tic blood pressure 
and heart rate checked and receive intravenous fluids as approp riate. These patients will also 
receive an ECG.
Hypotension is a common toxicity requiring intensive care unit (ICU) admission.  In general 
patients should be kept well-hydr ated.  Maintenan ce I.V. fluids (normal saline (NS) should be 
started on most patients with hig h fevers especially if oral in take is poor or the patient has 
tachycardia.  I.V. fluids are not necessary for patients with g ood oral intake and mild fevers.  
For patients who are not having hypotension or tumor lysis synd rome, a generally even fluid 
balance should be strived for aft er allowing for insensible flu id losses in patients with high
fevers.  The baseline systolic b lood pressure is defined for th is protocol as the average of all 
systolic blood pressure readings obtained during the 24 hours prior to the CAR T-cell infusion.  
The first treatment for hypoten sion is administration of IV NS boluses.  
xPatients with a systolic blood pr essure that is 80% or less of their baseline blood 
pressure and less than 100 mm Hg  should receive a 1 L NS bolus.  
xPatients with a systolic blood pr essure less than 85 mm Hg shou ld receive a 1 L NS 
bolus regardless of b aseline blood pressure. 
These I.V. fluid management s uggestions may need to be modified  based on the clinical 
characteristics of individual patients such as pulmonary status , cardiac function, edema and other 
factors.
10. Patients receiving fluid boluses for hypotension should have a stat EKG and troponin, and a 
cardiac echocardiogram within 24 hours.
11. Patients should be transferred to the ICU under these circums tances.  Patients not meeting 
these criteria could also require ICU admission at the discretio n of the clinical team caring 
for the patient.
xSystolic blood pressure 75% or le ss than the patientâ€™s baseline blood pressure and 
less than 100 mm Hg after admin istration of a 1L NS bolus.
xAnytime the systolic blood pressure is less than 85 mm Hg after  a 1L NS bolus.
xContinuous tachycardia with a heart rate higher than 125 beats per minute on 2 
occasions separated by at least 4 hours.
xOxygen requirement of more than a 4L standard nasal cannula
xGreater than grade 2 neurological toxicity
87
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
12. All patients transferred to the ICU for hypotension or tachyc ardia should have a stat EKG 
and a cardiac echocardiogram at the time of transfer.
13. Patients with hypotension not responding to IV fluid resusci tation should be started on 
norepinephrine at doses called for  by standard ICU guidelines.
14. Patients should have a cardiac  echocardiogram and an EKG withi n 24 hours of starting 
norepinephrine.
15. Patients in the ICU should get twice-daily labs (CBC with di fferential, acute care panel, 
mineral panel, hepatic panel, ur ic acid, LDH.  Patients in the ICU should also get a daily 
troponin level). 
16. Anecdotal evidence suggests that the IL-6 receptor blocker t ocilizumab can be an effective 
treatment for cytokine-release sy ndrome toxicities after CAR T- cell infusions. Tocilizumab 
should be administered under the fo llowing circumstances if the  listed disorders are thought 
to be due to cytokine release fro m CAR T cells.  Tocilizumab is  administered at a dose 8 
mg/kg infused IV over 1 hour  (dose should not exceed 800 mg).
xLeft ventricular ejection fraction 40% or less by echocardiogram
xCreatinine greater than 2.5-fold higher than the most recent le vel prior to CAR T-
cell infusion
xNorepinephrine requirement of 3 Pg/min or more for 36 hours since the first 
administration of norepinephrine even if norepinephrine adminis tration was not 
continuous.
xSystolic blood pressure of 90 mm Hg cannot be maintained with norepinephrine.
xOxygen requirement 55% or greater fraction of inspired oxygen (F IO2) for more 
than 2 continuous hours.
xDyspnea that is severe enough to potentially require mechanical  ventilation.
xPTT or INR>2x upper limit of normal
xClinically-significant bleeding
xCreatine kinase greater tha n 5x upper limit of normal for great er than 2 days
17. THERE IS NO EVIDENCE THAT TOCILIZUMAB HELPS NEUROLOGICAL 
TOXICITY, SO IT SHOULD NOT BE ADMINISTERED FOR THIS PURPOSE.
18. If no improvement in hypotension or tachycardia occurs within  6 hours of tocilizumab 
infusion, consider other agents such as methylprednisolone 1 mg/ kg every 12 hours or 
etanercept.
19. Avoid meperidine due to seizure risk.
20. In the setting of cytokine-release syndrome, patients with a  left ventricular ejection fraction 
of 30% or less and patients who in the opinion of an ICU physic ian is at significant risk of 
88
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
needing intubation in the next 4 hours should be given methylprednisolone 100 mg every 6 
hours.
21. Some patients may experience decreases in serum immunoglobul ins.  Replacement of 
serum IgG with intravenous IgG is recommended for serum IgG lev els below 400 mg/dL.  
22. In general, follow standard vaccination practices including an annual influenza vaccination 
in the absence of data t o suggest otherwise.
23. All patients with grade 2 or greater neurological toxicities  should get a neurology consult.
24. The following patients shoul d receive dexamethasone 10 mg in travenously every 6 hours 
until the toxicities improve to G rade 1 or resolve or until at least 8 doses of dexamethasone 
have been given.
1. Patients with Gra de 3 or 4 neurological toxicities except that  
dexamethasone is not reco mmended for iso lated Grade 3.
2. Any generalized seizure
89
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
13.4 APPENDIX D: I NFUSION INSTRUCTIONS   
Equipment:  
Primary IV tubing (2)Secondary IV tubing (1)NS (sodium chloride 0.9%) 250cc bags (2)IV infusion pumpGloves
Steps: Key Points:
1.  On the morning of infusion the primary 
RN will be notified of the approximate time TIL cells will be ready (usually between 11AM and noon).
2.  Verify the physician orders:
- to administer the cells- for the date of a dministration
- for premedication orders - protocol numberxPremeds are acetaminophen 650 mg 
PO and diphenhydramine 12.5 mg 
IV.
3.  Verify that the protocol consent and DPA are signed.
4.  Ensure that emergency and monitoringequipment are available in the patientâ€™s room:
- oxygen- suction- vital sign monitor with pulse oximeter
and thermometer   
90
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
5.  Provide patient e ducation covering 
infusion procedure, potential complications 
and associated symptoms to report. 
7.  Measure and record baseline vital signs, respiratory and circulatory assessments.
8.  Verify the patency of the patientâ€™s IV access.A central venous access device such as a non-valved PICC line should be used.
9.  Hang a primary line of 250cc NS at a kvo rate - NEW bag and NEW tubing. 
This MUST be ready and infusing prior to 
the cells being delivered to the unit.
The patientâ€™s primary IV hydration can 
infuse via a separate lumen while the cells are infusing, but NO MEDs should be
administered during this time.
Have a second bag of 250cc NS and tubing 
ready as an emergency line.This will be the dedicated NS line for infusing the cells.  Under no circumstances are any other substances to be infused into the line.  
Cell death occurs quickly â€“ the infusion 
must be initiated immediately. 
Do not infuse medication during the cell 
infusion.  If emergency meds must be administered, use the hydration or emergency NS IV line. 
This will be the emergency IV solution 
and can be used for medicationadministration.
Do not use an inline filter for cells.
10.  The primary RN will be notified 
approximately 10 minutes before the cells arrive on the unit.  The cells will be hand delivered to the bedside.
It is critical to be at the bedside awaiting 
the arrival of the cells for infusion.  It is critical to be at the bedside awaiting the arrival of the cells for infusion; have baseline VS, assessment, and IV lines hooked up when the cells arrive.  Cell 
death occurs as soon as the cells are removed from the laboratory .  Initiate the 
infusion as quickly as possible .
12.  Prior to spiking the cell bag, two RNs will perform the identification procedure.  
91
Abbreviated Title: Anti-BCMA-CAR T cells 
Version Date: September 21, 2017
Both RNs must sign the tag on the cell bag.
13.   Infuse the cells by infusion pump over 
20  minutes.
a .  P i g g y b a c k  t h e  c e l l s  i n t o  t h e  dedicated NS line; use the backflush technique to prime the line.
b. While the cells are infusing, gently
a g i t a t e  t h e  b a g  o f  c e l l s  every few 
minutes to prevent clumping in the bag. When the cell bag is empty, 
backflush NS to rinse the bag and infuse this at the same rate as the cells; rinse bag until NS runs clear.
Note, when very small cell doses are 
given, the cells will arrive at the bedside in a syringe.  In these cases, the cells should be manually infusedover 20 minutes via the syringe.
14.  Measure and record VS before and after the cell infusion, q1h x 4and then q4h after completion of the infusion.  
a.  Assess and document the    patientâ€™s respiratory and circulatory status post cell infusion.
15.  Documentation:
a.  After the cells have infused, remove the adhesive backed â€œcell therapy productâ€ tag from the cell bag and place it on a progress note in the patientâ€™s chart. 
b.  Document the cell infusion in  
CRIS using the appropriate screens.  